

PUBLICATIONS **INTERNATIONALES 2018**

INTERNATIONAL PUBLICATIONS 2018



GUSTAVE
ROUSSY
CANCER CAMPUS
GRAND PARIS



Publications internationales

Gustave Roussy 2018 avec impact factor 2017 supérieur à 30 (hors congrès)

International publications

Gustave Roussy 2018 with an impact factor 2017 > 30 (except meetings/poster abstracts)

1. **Alberro J., Early Breast Cancer Trialists' Collaborative Group (EBCTCG), [...], Andre F., Arriagada R., Delaloge S., Hill C., Koscielny S., Michiels S., and Rubino C.** Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. [2018] *Lancet Oncology* (19) 1 : 27-39
2. **Andre F.** Developing anticancer drugs in orphan molecular entities - A paradigm under construction. [2018] *New England Journal of Medicine* (378) 8 : 763-765
3. **Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K.H., de Wit M., Cho B.C., Bourhaba M., Quantin X., Tokito T., Mekhail T., Planchard D., Kim Y.C., Karapetis C.S., Hirt S., Ostoros G., Kubota K., Gray J.E., Paz-Ares L., de Castro Carpeno J., Faivre-Finn C., Reck M., Vansteenkiste J., Spigel D.R., Wadsworth C., Melillo G., Taboada M., Dennis P.A., Ozguroglu M., and PACIFIC Investigators.** Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NS-CLC. [2018] *New England Journal of Medicine* (379) 24 : 2342-2350
4. **Ascierto P.A. and Eggermont A.M.M.** Neoadjuvant therapy in melanoma: the next step? [2018] *Lancet Oncology* (19) 2 : 151-153
5. **Azoulay E., Lemiale V., Mokart D., Nseir S., Argaud L., Pene F., Kontar L., Bruneel F., Klouche K., Barbier F., Reignier J., Berahil-Meksen L., Louis G., Constantin J.M., Mayaux J., Wallet F., Kouatchet A., Peigne V., Theodose I., Perez P., Girault C., Jaber S., Oziel J., Nyunga M., Terzi N., Bouadma L., Lebert C., Lautrette A., Bige N., Raphaelen J.H., Papazian L., Darmon M., Chevret S., and Demoule A.** Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients with Acute Respiratory Failure: The HIGH Randomized Clinical Trial. [2018] *Jama* (320) 20 : 2099-2107
6. **Baghdadi M.B., Castel D., Machado L., Fukada S.I., Birk D.E., Relaix F., Tajbakhsh S., and Mourikis P.** Reciprocal signalling by Notch-Collagen V-CALCR retains muscle stem cells in their niche. [2018] *Nature* (557) 7707 : 714-718
7. **Bantug G.R., Galluzzi L., Kroemer G., and Hess C.** The spectrum of T cell metabolism in health and disease. [2018] *Nature Reviews Immunology* (18) 1 : 19-34
8. **Bisogno G., Jenney M., Bergeron C., Melcon S.G., Ferrari A., Oberlin O., Carli M., Stevens M., Kelsey A., De Paoli A., Gaze M.N., Martelli H., Devalck C., Merks J.H., Ben-Arush M., Glosli H., Chisholm J., Orbach D., Minard-Colin V., De Salvo G.L., Cesen M., Rose A., Ferman S., Mudry P., Sejnova D., Dal Bianco P., Zanetti I., Niggli F., Rogers T., Cecchetto G., De Corti F., Guerin F., Terwisscha S., Ranchere D., Alaggio R., Shipley J., Rosolen A., Mandeville H., Scarzello G., Bernier V., and McHugh K.** Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. [2018] *Lancet Oncology* (19) 8 : 1061-1071
9. **Blanchard P. and Tao Y.** Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts? [2018] *Lancet Oncology* (19) 4 : 429-431
10. **Boland B., Yu W.H., Corti O., Mollereau B., Henriques A., Bezaud E., Pastores G.M., Rubinsztein D.C., Nixon R.A., Duchon M.R., Mallucci G.R., Kroemer G., Levine B., Eskelinen E.L., Mochel F., Spedding M., Louis C., Martin O.R., and Millan M.J.** Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. [2018] *Nature Reviews Drug Discovery* (17) 9 : 660-688
11. **Brock P.R., Maibach R., Childs M., Rajput K., Roebuck D., Sullivan M.J., Laithier V., Ronghe M., Dall'Igna P., Hiyama E., Brichard B., Skeen J., Mateos M.E., Capra M., Rangaswami A.A., Ansari M., Rechner C., Veal G.J., Covezzoli A., Brugieres L., Perilongo G., Czauderna P., Morland B., and Neuwelt E.A.** Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. [2018] *New England Journal of Medicine* (378) 25 : 2376-2385
12. **Cerezo M., Guemiri R., Druillenec S., Girault I., Malka-Mahieu H., Shen S., Allard D., Martineau S., Welsch C., Agoussi S., Estrada C., Adam J., Libenciuc C., Routier E., Roy S., Desaubry L., Eggermont A.M., Sonenberg N., Scoazec J.Y., Eychene A., Vagner S., and Robert C.** Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. [2018] *Nature Medicine* (24) 12 : 1877-1886
13. **Chamseddine A.N., Loulergue P., and Mir O.** HIV-Associated Cancers and Related Diseases. [2018] *New England Journal of Medicine* (378) 22 : 2144-2144
14. **Chi K.N., Protheroe A., Rodriguez-Antolin A., Facchini G., Suttman H., Matsubara N., Ye Z., Keam B., Damiao R., Li T., McQuarrie K., Jia B., De Porre P., Martin J., Todd M.B., and Fizazi K.** Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. [2018] *Lancet Oncology* (19) 2 : 194-206
15. **Conroy T., Hammel P., Hebbbar M., Ben Abdelghani M., Wei A.C., Raoul J.L., Chone L., Francois E., Artru P., Biagi J.J., Lecomte T., Assenat E., Faroux R., Ychou M., Volet J., Sauvanet A., Breysacher G., Di Fiore F., Cripps C., Kavan P., Texereau P., Bouhier-Leporrier K., Khemissa-Akouf F., Legoux J.L., Juzyna B., Gourgou S., O'Callaghan C.J., Jouffroy-Zeller C., Rat P., Malka D., Castan F., and Bachtet J.B.** FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. [2018] *New England Journal of Medicine* (379) 25 : 2395-2406
16. **Coquel F., Silva M.J., Techer H., Zadorozhny K., Sharma S., Nieminuszczy J., Mettling C., Dardillac E., Barthe A., Schmitz A.L., Promonet A., Cribier A., Sarrazin A., Niedzwiedz W., Lopez B., Costanzo V., Krejci L., Chabes A., Benkirane M., Lin Y.L., and Pasero P.** SAMHD1 acts at stalled replication forks to prevent interferon induction. [2018] *Nature* (557) 7703 : 57-61
17. **Dardaei L., Wang H.Q., Singh M., Fordjour P., Shaw K.X., Yoda S., Kerr G., Yu K., Liang J., Cao Y., Chen Y., Lawrence M.S., Langenbucher A., Gainor J.F., Friboulet L., Dagogo-Jack I., Myers D.T., Labrot E., Ruddy D., Parks M., Lee D., Dicecca R.H., Moody S., Hao H., Mohseni M., Lamarche M., Williams J., Hoffmaster K., Caponigro G., Shaw A.T., Hata A.N., Benes C.H., Li F., and Engelman J.A.** SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. [2018] *Nature Medicine* (24) 4 : 512-517

18. **de Boer S.M., [...], Haie-Meder C., and Tubiana-Mathieu N.** Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer [PORTEC-3]: final results of an international, open-label, multicentre, randomised, phase 3 trial. [2018] *Lancet Oncology* (19) 3 : 295-309
19. **DiNardo C., Stein E., de Botton S., Roboz G., Altman J., Mims A., Swords R., Collins R., Mannis G., Pollyea D., Donnellan W., Faith A., Pigneux A., Erba H., Prince G., Stein A., Uy G., Foran J., Traer E., Stuart R., Arelano M., Slack J., Sekeres M., Willekens C., Choe S., Wang H., Zhang V., Yen K., Kapsalis S., Yang H., Dai D., Fan B., Goldwasser M., Liu H., Agresta S., Wu B., Attar E., Tallman M., Stone R., and Kantarjian H.** Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. [2018] *New England Journal of Medicine* (378) 25 : 2386-2398
20. **Dummer R., Ascierto P.A., Gogas H.J., Arance A., Mandala M., Liskay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R., Chiarion-Sileni V., Dutriaux C., de Groot J.W.B., Yamazaki N., Loquai C., Moutouh-de Parseval L.A., Pickard M.D., Sandor V., Robert C., and Flaherty K.T.** Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. [2018] *Lancet Oncology* (19) 5 : 603-615
21. **Dummer R., Ascierto P.A., Gogas H.J., Arance A., Mandala M., Liskay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R., Chiarion S., V, Dutriaux C., de Groot J.W.B., Yamazaki N., Loquai C., Moutouh-de Parseval L.A., Pickard M.D., Sandor V., Robert C., and Flaherty K.T.** Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. [2018] *Lancet Oncology* (19) 10 : 1315-1327
22. **Eggermont A.M.M., Robert C., and Succi S.** Adjuvant Pembrolizumab in Resected Stage III Melanoma. [2018] *New England Journal of Medicine* (379) 6 : 593-595
23. **Eggermont A.M.M., Blank C.U., Mandala M., Long G.V., Atkinson V., Dalle S., Haydon A., Lichinitser M., Khattak A., Carlino M.S., Sandhu S., Larkin J., Puig S., Ascierto P.A., Rutkowski P., Schadendorf D., Koornstra R., Hernandez-Aya L., Maio M., van den Eertwegh A.J.M., Grob J.J., Gutzmer R., Jamal R., Lorigan P., Ibrahim N., Marreaud S., van Akkooi A.C.J., Succi S., and Robert C.** Adjuvant pembrolizumab versus placebo in resected stage III melanoma. [2018] *New England Journal of Medicine* (378) 19 : 1789-1801
24. **Escudier B., Thezenas S., and Mejean A.** Sunitinib Alone or after Nephrectomy in Renal Cancer. [2018] *New England Journal of Medicine* (379) 19 : 1878
25. **Fanti S., Minozzi S., Antoch G., Banks I., Briganti A., Carrio I., Chiti A., Clarke N., Eiber M., De Bono J., Fizazi K., Gillessen S., Gledhill S., Haberkorn U., Herrmann K., Hicks R.J., Lecouvet F., Montironi R., Ost P., O'Sullivan J.M., Padhani A.R., Schalken J.A., Scher H.I., Tombal B., van Moorselaar R.J.A., Van Poppel H., Vargas H.A., Walz J., Weber W.A., Wester H.J., and Oyen W.J.G.** Consensus on molecular imaging and theranostics in prostate cancer. [2018] *Lancet Oncology* (19) 12 : e696-e708
26. **Galluzzi L., Yamazaki T., and Kroemer G.** Linking cellular stress responses to systemic homeostasis. [2018] *Nature Reviews Molecular Cell Biology* (19) 11 : 731-745
27. **Gelderblom H., Cropet C., Chevreau C., Boyle R., Tattersall M., Stacchiotti S., Italiano A., Piperno-Neumann S., Le Cesne A., Ferraresi V., Penel N., Duffaud F., Cassier P., Toulmonde M., Casali P., Taieb S., Guillemaut S., Metzger S., Perol D., and Blay J.Y.** Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. [2018] *Lancet Oncology* (19) 5 : 639-648
28. **Gopalakrishnan V., [...], Zitvogel L., [...], and Wargo J.A.** Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. [2018] *Science* (359) 6371 : 97-103
29. **Groebner S.N., [...], Vassal G., [...], and Pfister S.M.** The landscape of genomic alterations across childhood cancers. [2018] *Nature* (555) 7696 : 321-327
30. **Hendriks L. and Besse B.** New windows open for immunotherapy in lung cancer. [2018] *Nature* (558) 7710 : 376-377
31. **Hendriks L.E. and Besse B.** Clinical oncology. Windows open for cancer immunotherapy. [2018] *Nature* (558) 7710 : 376-377
32. **Hussain M., Fizazi K., Saad F., Rathenborg P., Shore N., Ferreira U., Ivashchenko P., Demirhan E., Modelska K., Phung, Krivoshik A., and Sternberg C.N.** Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. [2018] *New England Journal of Medicine* (378) 26 : 2465-2474
33. **Italiano A., Soria J.C., Toulmonde M., Michot J.M., Lucchesi C., Varga A., Coindre J.M., Blakemore S.J., Clawson A., Suttle B., McDonald A.A., Woodruff M., Ribich S., Hedrick E., Keilhack H., Thomson B., Owa T., Copeland R.A., Ho P.T.C., and Ribrag V.** Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. [2018] *Lancet Oncology* (19) 5 : 649-659
34. **Kolb F., Simon F., Gaudin R., Thierry B., Mussot S., Dupic L., Coste J.L., Denoyelle F., Couloigner V., and Garabedian E.N.** 4-year follow-up in a child with a total autologous tracheal replacement. [2018] *New England Journal of Medicine* (378) 14 : 1355-1357
35. **Kroemer G., Lopez-Otin C., Madeo F., and de Cabo R.** Carbotoxicity-Noxious Effects of Carbohydrates. [2018] *Cell* (175) 3 : 605-614
36. **Kroemer G. and Zitvogel L.** Cancer immunotherapy in 2017: The breakthrough of the microbiota. [2018] *Nature Reviews Immunology* (18) 2 : 87-88
37. **Kroemer G. and Zitvogel L.** The breakthrough of the microbiota. [2018] *Nature Reviews Immunology* (18) 2 : 87-88
38. **Ladenstein R., Potschger U., Valteau-Couanet D., Luksch R., Castel V., Yaniv I., Laureys G., Brock P., Michon J.M., Owens C., Trahair T., Chan G.C.F., Ruud E., Schroeder H., Beck P.M., Schreier G., Loibner H., Ambros P., Holmes K., Castellani M.R., Gaze M.N., Garaventa A., Pearson A.D.J., and Lode H.N.** Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SI-OPEN): a multicentre, randomised, phase 3 trial. [2018] *Lancet Oncology* (19) 12 : 1617-1629
39. **Lawler M., Morris A.D., Sullivan R., Birney E., Middleton A., Makaroff L., Knoppers B.M., Horgan D., and Eggermont A.** A roadmap for restoring trust in Big Data. [2018] *Lancet Oncology* (19) 8 : 1014-1015
40. **Madeo F., Eisenberg T., Pietrocola F., and Kroemer G.** Spermidine in health and disease. [2018] *Science* (359) 6374 : eaan2788
41. **Mariathasan S., Turley S.J., Nickles D., Castiglioni A., Yuen K., Wang Y., Kadel E.E., Koeppen H., Astarita J.L., Cubas R., Jhunjhunwala S., Banichereau R., Yang Y., Guan Y., Chalouni C., Ziai J., Senbabaoglu Y., Santoro S., Sheinson D., Hung J., Giltman J.M., Pierce A.A., Mesh K., Lianoglou S., Riegler J., Carano R.A., Eriksson P., Hognlund M., Sommariba L., Halligan D.L., van der Heijden M.S., Lorient Y., Rosenberg J.E., Fong L., Mellman I., Chen D.S., Green M., Derleth C., Fine G.D., Hegde P.S., Bourgon R., and Powles T.** TGF beta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. [2018] *Nature* (554) 7693 : 544-548
42. **McDermott D.F., Huseni M.A., Atkins M.B., Motzer R.J., Rini B.I., Escudier B., Fong L., Joseph R.W., Pal S.K., Reeves J.A., Sznol M., Hainsworth J., Rathmell W.K., Stadler W.M., Hutson T., Gore M.E., Ravaud A., Bracarda S., Suarez C., Danielli R., Gruenwald V., Choueiri T.K., Nickles D., Jhunjhunwala S., Piault-Louis E., Thobhani A., Qiu J., Chen D.S., Hegde P.S., Schiff C., Fine G.D., and Powles T.** Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. [2018] *Nature Medicine* (24) 6 : 749-757
43. **Mejean A., Ravaud A., Thezenas S., Colas S., Beauval J.B., Bensalah K., Geoffrois L., Thiery-Vuillemin A., Cormier L., Lang H., Guy L., Gravis G., Rolland F., Linossier C., Lechevallier E., Beisland C., Aitchison M., Oudard S., Patard J.J., Theodore C., Chevreau C., Laguerre B., Hubert J., Gross-Goupil M., Bernhard J.C., Albiges L., Timsit M.O., Leuret T., and Escudier B.** Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. [2018] *New England Journal of Medicine* (379) 5 : 417-427

44. Moore K., Colombo N., Scambia G., Kim B.G., Oaknin A., Friedlander M., Lisynskaya A., Floquet A., Leary A., Sonke G.S., Gourley C., Banerjee S., Oza A., Gonzalez-Martin A., Aghajanian C., Bradley W., Mathews C., Liu J., Lowe E.S., Bloomfield R., and DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. [2018] *New England Journal of Medicine* (379) 26 : 2495-2505
45. Morschhauser F., Fowler N.H., Feugier P., Bouabdallah R., Tilly H., Palomba M.L., Fruchart C., Libby E.N., Casasnovas R.O., Flinn I.W., Haioun C., Maisonneuve H., Ysebaert L., Bartlett N.L., Bouabdallah K., Brice P., Ribrag V., Daguindau N., Gouill S.L., Pica G.M., Garcia-Sancho A.M., Lopez-Guillermo A., Larouche J.F., Ando K., da Silva M.G., Andre M., Zachee P., Sehn L.H., Tobinai K., Cartron G., Liu D., Wang J., Xerri L., and Salles G.A. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. [2018] *New England Journal of Medicine* (379) 10 : 934-946
46. Motzer R.J., Tannir N.M., McDermott D.F., Aren Frontera O., Melichar B., Choueiri T.K., Plimack E.R., Barthelemy P., Porta C., George S., Powles T., Donskov F., Neiman V., Kollmannsberger C.K., Salman P., Gurney H., Hawkins R., Ravaud A., Grimm M.O., Braccarda S., Barrios C.H., Tomita Y., Castellano D., Rini B.I., Chen A.C., Mekan S., McHenry M.B., Wind-Rotolo M., Doan J., Sharma P., Hammers H.J., Escudier B., and CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. [2018] *New England Journal of Medicine* (378) 14 : 1277-1290
47. Nikolaev S.I., Fish J.E., and Radovanovic I. Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain. [2018] *New England Journal of Medicine* (378) 16 : 1561-1562
48. Nikolaev S.I., Vetiska S., Bonilla X., Boudreau E., Jauhiainen S., Rezai J.B., Khyzha N., DiStefano P.V., Suutarinen S., Kiehl T.R., Mendes P., V Herman A.M., Krings T., Andrade-Barazarte H., Tung T., Valiante T., Zadeh G., Tymianski M., Rauramaa T., Yla-Herttuala S., Wythe J.D., Antonarakis S.E., Frosen J., Fish J.E., and Radovanovic I. Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain. [2018] *New England Journal of Medicine* (378) 3 : 250-261
49. Pearson A.D., Heenen D., Kearns P.R., Goeres A., Marshall L.V., Blanc P., and Vassal G. 10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers. [2018] *Lancet Oncology* (19) 3 : 285-287
50. Powles T., Duran I., van der Heijden M.S., Loriot Y., Vogelzang N.J., De Giorgi U., Oudard S., Retz M.M., Castellano D., Bamias A., Flechon A., Gravis G., Hussain S., Takano T., Leng N., Kadel E.E., Banchereau R., Hegde P.S., Mariathasan S., Cui N., Shen X., Derleth C.L., Green M.C., and Ravaud A. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. [2018] *Lancet* (391) 10122 : 748-757
51. Quek L., David M.D., Kennedy A., Metzner M., Amatangelo M., Shih A., Stoilova B., Quivron C., Heiblig M., Willekens C., Saada V., Alsafadi S., Vijayabaskar M.S., Peniket A., Bernard O.A., Agresta S., Yen K., MacBeth K., Stein E., Vassiliou G.S., Levine R., de Botton S., Thakurta A., Penard-Lacronique V., and Vyas P. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. [2018] *Nature medicine* (24) 8 : 1167-1177
52. Robert C. and Vagner S. Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases. [2018] *Cell* (175) 4 : 901-902
53. Robert C. Is earlier better for melanoma checkpoint blockade? [2018] *Nature Medicine* (24) 11 : 1645-1648
54. Robert C. Management of sentinel-node metastasis in melanoma: A woman with melanoma and sentinel-node metastasis. Option 2 : Recommend Observation of the Nodes with Ultrasonography. [2018] *New England Journal of Medicine* (378) 1 : 87-88
55. Romani L., Stincardini C., Giovagnoli S., Paci M., Vilella V.R., Sforza L., Renga G., Bellet M.M., Costantini C., Puccetti P., Kroemer G., Maiuri L., Pessia M., Goldstein A., and Garaci E. Reply to 'F508del-CFTR is not corrected by thymosin a1'. [2018] *Nature Medicine* (24) 7 : 891-893
56. Routy B., Le Chatelier E., Derosa L., Duong C.P.M., Alou M.T., Daillere R., Fluckiger A., Messaoudene M., Rauber C., Roberti M.P., Fidelle M., Flament C., Poirier-Colame V., Opolon P., Klein C., Iribarren K., Mondragon L., Jacquilot N., Qu B., Ferrere G., Clemenson C., Mezquita L., Masip J.R., Naltet C., Brosseau S., Kaderbhai C., Richard C., Rizvi H., Levenez F., Galleron N., Quinquis B., Pons N., Ryffel B., Minard-Colin V., Gonin P., Soria J.C., Deutsch E., Loriot Y., Ghiringhelli F., Zalcman G., Goldwasser F., Escudier B., Hellmann M.D., Eggermont A., Raoult D., Albiges L., Kroemer G., and Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. [2018] *Science* (359) 6371 : 91-97
57. Salgado R., Moore H., Martens J.W.M., Lively T., Malik S., McDermott U., Michiels S., Moscow J.A., Tejpar S., McKee T., and Lacombe D. Steps forward for cancer precision medicine. [2018] *Nature Reviews Drug Discovery* (17) 1 : 1-2
58. Solomon B.J., Besse B., Bauer T.M., Felip E., Soo R.A., Camidge D.R., Chiari R., Bearz A., Lin C.C., Gadgeel S.M., Riely G.J., Tan E.H., Seto T., James L.P., Clancy J.S., Abbattista A., Martini J.F., Chen J., Peltz G., Thurm H., Ignatius Ou S.H., and Shaw A.T. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. [2018] *Lancet Oncology* (19) 12 : 1654-1667
59. Soria J.C., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee K.H., Dechaphunkul A., Imamura F., Nogami N., Kurata T., Okamoto I., Zhou C., Cho B.C., Cheng Y., Cho E.K., Voon P.J., Planchard D., Su W.C., Gray J.E., Lee S.M., Hodge R., Marotti M., Rukazekov Y., and Ramalingam S.S. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. [2018] *New England Journal of Medicine* (378) 2 : 113-125
60. Soria J.C. and Ramalingam S.S. Osimertinib in EGFR Mutation-Positive Advanced NSCLC. [2018] *New England Journal of Medicine* (378) 13 : 1262-1263
61. Sun R., Limkin E.J., Vakalopoulou M., Dercle L., Champiat S., Han S.R., Verlingue L., Brandao D., Lancia A., Ammari S., Hollebecque A., Scoazec J.Y., Marabelle A., Massard C., Soria J.C., Robert C., Paragios N., Deutsch E., and Ferte C. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. [2018] *Lancet Oncology* (19) 9 : 1180-1191
62. Turner N.C., Slamon D.J., Ro J., Bondarenko I., Im S.A., Masuda N., Colleoni M., DeMichele A., Loi S., Verma S., Iwata H., Harbeck N., Loi B., Andre F., Puyana T.K., Huang X., Giobbetti C., Huang B.C., and Cristofanilli M. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. [2018] *New England Journal of Medicine* (379) 20 : 1926-1936
63. Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., Groebner S., Grund K.B., Brugieres L., Jones D.T.W., Pajtlar K.W., Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerri-Rousseau L., Fults D.W., Grajkowska K., Hauser P., Jabado N., Ra Y.S., Zitterbart K., Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., MacDonald T.J., Hernaiz Driever P., Bendel A.E., Bowers D.C., McCowage G., Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., Wesenberg F., Feychting M., Lannering B., Schuz J., Johansen C., Andersen T.V., Roosli M., Kuehni C.E., Grotzer M., Kjaerheim K., Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., Sumerauer D., Scheurle W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., Lichter P., Malkin D., Gajjar A., Korbel J.O., and Pfister S.M. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. [2018] *Lancet Oncology* (19) 6 : 785-798
64. Zitvogel L., Ma Y., Raoult D., Kroemer G., and Gajewski T.F. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. [2018] *Science* (359) 6382 : 1366-1370

**Publications internationales
Gustave Roussy 2018 avec impact factor 2017
compris entre 20 et 30
(hors congrès)**

**International publications
Gustave Roussy 2018 with an impact factor 2017
between 20 and 30
(except meetings/poster abstracts)**

1. **Albiges L., Flippot R., Rioux-Leclercq N., and Choueiri T.K.** Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. [2018] *Journal of Clinical Oncology* (36) 36 : 3624-3631
2. **Aparicio T., Ghiringhelli F., Boige V., Le Malicot K., Taieb J., and Bennouna J.** Reply to M. Mo et al. [2018] *Journal of Clinical Oncology* (36) 23 : 2452-2453
3. **Aparicio T., Ghiringhelli F., Boige V., Le Malicot K., Taieb J., Bouche O., Phelip J.M., François E., Borel C., Faroux R., Dahan L., Jacquot S., Genet D., Khemissa F., Suc E., Desseigne F., Texereau P., Lepage C., and Bennouna J.** Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: A randomized phase III trial (PRODIGE 9). [2018] *Journal of Clinical Oncology* (36) 7 : 674-681
4. **Arbour K.C., Mezquita L., Long N., Rizvi H., Auclin E., Ni A., Martinez-Bernal G., Ferrara R., Lai W.V., Hendriks L.E.L., Sabari J.K., Caramella C., Plodkowski A.J., Halpenny D., Chaft J.E., Planchard D., Riely G.J., Besse B., and Hellmann M.D.** Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. [2018] *Journal of Clinical Oncology* (36) 28 : 2872-2878
5. **Attard G., Borre M., Gurney H., Loriot Y., Andresen-Daniil C., Kallela R., Pham T., and Taplin M.E.** Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. [2018] *Journal of Clinical Oncology* (36) 25 : 2639-2646
6. **Baghdadi M.B., Firmino J., Soni K., Evans B., Di Girolamo D., Mourikis P., Castel D., and Tajbakhsh S.** Notch-Induced miR-708 Antagonizes Satellite Cell Migration and Maintains Quiescence. [2018] *Cell Stem Cell* (23) 6 : 859-868
7. **Bibault J.E. and Blanchard P.** Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking? [2018] *Journal of Clinical Oncology* (36) 22 : 2348-2349
8. **Cella D., Escudier B., Tannir N.M., Powles T., Donskov F., Peltola K., Schmidinger M., Heng D.Y.C., Mainwaring P.N., Hammers H.J., Lee J.L., Roth B.J., Marteau F., Williams P., Baer J., Mangeshkar M., Schefold C., Hutson T.E., Pal S., Motzer R.J., and Choueiri T.K.** Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial. [2018] *Journal of Clinical Oncology* (36) 8 : 757-764
9. **Champiat S., Ferrara R., Massard C., Besse B., Marabelle A., Soria J.C., and Ferte C.** Hyperprogressive disease: recognizing a novel pattern to improve patient management. [2018] *Nature Reviews Clinical Oncology* (15) 12 : 748-762
10. **Chargari C., Massard C., and Deutsch E.** Focus on the Number of Radiation Oncology Trials or on Clinical Relevance? [2018] *JAMA Oncology* (4) 12-1791
11. **Corcoran R.B., Andre T., Atreya C.E., Schellens J.H.M., Yoshino T., Bendell J.C., Hollebecque A., McRee A.J., Siena S., Middleton G., Muro K., Gordon M.S., Tabernero J., Yaeger R., O'Dwyer P.J., Humblet Y., de Vos F., Jung A.S., Brase J.C., Jaeger S., Bettinger S., Mookerjee B., Rangwala F., and Van Cutsem E.** Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. [2018] *Cancer Discovery* (8) 4 : 428-443
12. **Cortes J.R., Ambesi-Impombato A., Couronne L., Quinn S.A., Kim C.S., da Silva Almeida A.C., West Z., Belver L., Martin M.S., Scourzic L., Bhagat G., Bernard O.A., Ferrando A.A., and Palomero T.** RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. [2018] *Cancer Cell* (33) 2 : 259-273
13. **Devarakonda S., Rotolo F., Tsao M.S., Lanci I., Brambilla E., Masood A., Olaussen K.A., Fulton R., Sakashita S., McLeer-Florin A., Ding K., Le Teuff G., Shepherd F.A., Pignon J.P., Graziano S.L., Kratzke R., Soria J.C., Seymour L., Govindan R., and Michiels S.** Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. [2018] *Journal of Clinical Oncology* (36) 30 : 2995-3006
14. **Dominguez P.M., Ghamlouch H., Rosikiewicz W., Kumar P., Beguelin W., Fontan L., Rivas M.A., Pawlikowska P., Armand M., Mouly E., Torres-Martin M., Doane A.S., Calvo Fernandez M.T., Durant M., Della-Valle V., Teater M., Cimmino L., Droin N., Tadros S., Motanagh S., Shih A.H., Rubin M.A., Tam W., Aifantis I., Levine R.L., Elemento O., Inghirami G., Green M.R., Figueroa M.E., Bernard O.A., Aoufouchi S., Li S., Shakhnovich R., and Melnick A.M.** TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation and promotes B-cell lymphomagenesis. [2018] *Cancer Discovery* (8) 12 : 1632-1653
15. **Eggermont A.M.M., Robert C., and Ribbas A.** The new era of adjuvant therapies for melanoma. [2018] *Nature Reviews Clinical Oncology* (15) 9 : 535-536
16. **Escudier B., Powles T., Motzer R.J., Olencki T., Frontera O.A., Oudard S., Rolland F., Tomczak P., Castellano D., Appleman L.J., Drabkin H., Vaena D., Milwee S., Youkster J., Loughheed J.C., Bracarda S., and Choueiri T.K.** Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. [2018] *Journal of Clinical Oncology* (36) 8 : 765-772
17. **Fathi A.T., DiNardo C.D., Kline I., Kevin L., Gupta I., Attar E.C., Stein E.M., de Botton S., and AG221-C-001 Study Investigators.** Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. [2018] *JAMA Oncology* (4) 8 : 1106-1110
18. **Ferrara R., Mezquita L., Texier M., Lahmar J., Audigier-Valette C., Tessonier L., Mazieres J., Zalcman G., Brosseau S., Le Moulec S., Leroy L., Duchemann B., Lefebvre C., Veillon R., Westeel V., Koscielny S., Champiat S., Ferte C., Planchard D., Remon J., Boucher M.E., Gazzah A., Adam J., Bria E., Tortora G., Soria J.C., Besse B., and Caramella C.** Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. [2018] *JAMA Oncology* (4) 11 : 1543-1552

19. Forget A., Martignetti L., Puget S., Calzone L., Brabetz S., Picard D., Montagud A., Liva S., Sta A., Dingli F., Arras G., Rivera J., Loew D., Besnard A., Lacombe J., Pages M., Varlet P., Dufour C., Yu H., Mercier A.L., Indersie E., Chivet A., Leboucher S., Sieber L., Beccaria K., Gombert M., Meyer F.D., Qin N., Bartl J., Chavez L., Okonechnikov K., Sharma T., Thatikonda V., Bourdeaut F., Pouponnot C., Ramaswamy V., Korshunov A., Borkhardt A., Reifenberger G., Poulet P., Taylor M.D., Kool M., Pfister S.M., Kawachi D., Barillot E., Remke M., and Ayrault O. Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. [2018] *Cancer Cell* (34) 3 : 379-395
20. Frezza A.M., Jones R.L., Lo Vullo S., Asano N., Lucibello F., Ben-Ami E., Ratan R., Teterycz P., Boye K., Brahmi M., Palmerini E., Fedenko A., Vincenzi B., Brunello A., Desai I.M.E., Benjamin R.S., Blay J.Y., Broto J.M., Casali P.G., Gelderblom H., Grignani G., Gronchi A., Hall K.S., Mir O., Rutkowski P., Wagner A.J., Anurova O., Collini P., Dei Tos A.P., Flucke U., Hornick J.L., Lobmaier I., Terrier P., Picci P., Ranchere D., Renne S.L., Sbaraglia M., Thway K., Wagrodzki M., Wang W.L., Yoshida A., Mariani L., Kawai A., and Stacchiotti S. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. [2018] *JAMA Oncology* (4) 9 : e180219
21. Geoffrois L., Martin L., De Raucourt D., Sun X.S., Tao Y., Maingon P., Buffet J., Poinreau Y., Sire C., Tuchais C., Babin E., Coutte A., Rolland F., Kaminsky M.C., Alfonsi M., Lapeyre M., Saliou M., Lafond C., Jadaud E., Gery B., Zawadi A., Tourani J.M., Khoury C., Henry A.R., Hasbini A., Guichard F., Borel C., Meert N., Guillet P., Calais M.H., Garaud P., and Bourhis J. Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial. [2018] *Journal of Clinical Oncology* (36) 31 : 3077-3083
22. Goss G.D., Felip E., Cobo M., Lu S., Syrigos K., Lee K.H., Goker E., Georgoulas V., Li W., Guclu S., Isla D., Min Y.J., Morabito A., Ardizzoni A., Gadgeel S.M., Fulop A., Buhemann C., Gibson N., Kramer N., Solca F., Cseh A., Ehrnrooth E., and Soria J.C. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. [2018] *JAMA Oncology* (4) 9 : 1189-1197
23. Grill J., Massimino M., Bouffet E., Azizi A.A., McCowage G., Canete A., Saran F., Le Deley M.C., Varlet P., Morgan P.S., Jaspan T., Jones C., Giangaspero F., Smith H., Garcia J., Elze M.C., Rousseau R.F., Abrey L., Hargrave D., and Vassal G. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. [2018] *Journal of Clinical Oncology* (36) 10 : 951-958
24. Haas R.L., Gronchi A., van de Sande M.A.J., Baldini E.H., Gelderblom H., Mes-siou C., Wardelmann E., and Le Cesne A. Perioperative management of extremity soft tissue sarcomas. [2018] *Journal of Clinical Oncology* (36) 2 : 118-124
25. Hauschild A., Dummer R., Schadendorf D., Santinami M., Atkinson V., Mandala M., Chiarion-Sileni V., Larkin J., Nyakas M., Dutriaux C., Haydon A., Robert C., Mortier L., Schachter J., Lesimple T., Plummer R., Dasgupta K., Haas T., Shilkrut M., Gasal E., Kefford R., Kirkwood J.M., and Long G.V. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. [2018] *Journal of Clinical Oncology* (36) 35 : 3441-3449
26. Heller G., McCormack R., Kheoh T., Molina A., Smith M.R., Dreicer R., Saad F., de Wit M., Aftab D.T., Hirmand M., Limon A., Fizazi K., Fleisher M., de Bono J.S., and Scher H.I. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. [2018] *Journal of Clinical Oncology* (36) 6 : 572-580
27. Heller G., McCormack R., Kheoh T., Molina A., Smith M.R., Dreicer R., Saad F., De Wit R., Aftab D.T., Hirmand M., Limon-Carrera A., Fizazi K., Fleisher M., de Bono J.S., and Scher H.I. Reply to C. Ren et al. [2018] *Journal of Clinical Oncology* (36) 22 : 2354-2356
28. Heller G., McCormack R., Kheoh T., Molina A., Smith M.R., Dreicer R., Saad F., de Wit R., Aftab D.T., Hirmand M., Limon-Carrera A., Fizazi K., Fleisher M., de Bono J.S., and Scher H.I. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply. [2018] *Journal of Clinical Oncology* (36) 22 : 2354-2355
29. Hoffman L.M., [...], Grill J., [...] and Fouladi M. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. [2018] *Journal of Clinical Oncology* (36) 19 : 1963-1972
30. Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida F., [...], Severi G., Boutron-Ruault M.C., [...], and Hanash S.M. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. [2018] *JAMA Oncology* (4) 10 : e182078
31. Kaley T., Touat M., Subbiah V., Hollebecque A., Rodon J., Lockhart A.C., Keedy V., Bielle F., Hofheinz R.D., Joly F., Blay J.Y., Chau I., Puzanov I., Rajee N.S., Wolf J., DeAngelis L.M., Makrutzki M., Riehl T., Pitcher B., Baselga J., and Hyman D.M. BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study. [2018] *Journal of Clinical Oncology* (36) 35 : 3477-3484
32. Lamartina L., Grani G., Durante C., Borget I., Filetti S., and Schlumberger M. Follow-up of differentiated thyroid cancer - what should (and what should not) be done. [2018] *Nature Reviews Endocrinology* (14) 9 : 538-551
33. Levy A., Bonvalot S., Callegaro D., Botticella A., Le Cesne A., Gronchi A., and Le Pechoux C. Consistent Margin-Status Reporting in Soft Tissue Sarcoma Is Essential to Establish Risk-Adapted Strategies Integrating Biology and Histotype in Perioperative Treatments. [2018] *Journal of Clinical Oncology* (36) 22 : 2357-2358
34. Lewin J., Soria J.C., Stathis A., Delord J.P., Peters S., Awada A., Aftimos P.G., Bekradda M., Rezaei K., Zeng Z., Hussain A., Perez S., Siu L.L., and Massard C. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. [2018] *Journal of Clinical Oncology* (36) 30 : 3007-3014
35. Lopez-Soto A. and Kroemer G. Cancer-Induced Endoplasmic Reticulum Stress in T Cells Subverts Immunosurveillance. [2018] *Cell Metabolism* (28) 6 : 803-805
36. Mackay A., Burford A., Molinari V., Jones D.T.W., Izquierdo E., Brouwer-Visser J., Giangaspero F., Haberler C., Pietsch T., Jacques T.S., Figarella-Branger D., Rodriguez D., Morgan P.S., Raman P., Waanders A.J., Resnick A.C., Massimino M., Garre M.L., Smith H., Capper D., Pfister S.M., Wurdinger T., Tam R., Garcia J., Thakur M.D., Vassal G., Grill J., Jaspan T., Varlet P., and Jones C. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. [2018] *Cancer Cell* (33) 5 : 829-842
37. Maes T., Mascaro C., Tirapu I., Estiarte A., Ciceri F., Lunardi S., Guibourt N., Perdomes A., Lufino M.M.P., Somerville T.C.P., Wiseman D.H., Duy C., Melnick A., Willekens C., Ortega A., Martinell M., Valls N., Kurz G., Fyfe M., Castro-Palomino J.C., and Buesa C. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. [2018] *Cancer Cell* (33) 3 : 495-511
38. Mezquita L., Auclin E., Ferrara R., Charrier M., Remon J., Planchard D., Ponce S., Ares L.P., Leroy L., Audigier-Valette C., Felip E., Zeron-Medina J., Garrido P., Brosseau S., Zalcman G., Mazieres J., Caramela C., Lahmar J., Adam J., Chaput N., Soria J.C., and Besse B. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. [2018] *JAMA Oncology* (4) 3 : 351-357

39. **Mir O., Adam J., and Honore C.** Optimal Multimodal Treatment for Desmoplastic Small Round Cell Tumors. [2018] *JAMA Oncology* (4) 9 : 1301
40. **O'Leary B., Cutts R.J., Liu Y., Hrebien S., Huang X., Fenwick K., Andre F., Loibl S., Loi S., Garcia-Murillas I., Cristofanilli M., Huang B.C., and Turner N.C.** The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. [2018] *Cancer Discovery* (8) 11 : 1390-1403
41. **Petrylak D.P., Powles T., Bellmunt J., Braiteh F., Loriot Y., Morales-Barrera R., Burris H.A., Kim J.W., Ding B., Kaiser C., Fasso M., O'Hear C., and Vogelzang N.J.** Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. [2018] *JAMA Oncology* (4) 4 : 537-544
42. **Planchard D.** Have We Really MET a New Target? [2018] *Journal of Clinical Oncology* (36) 31 : 3069-3071
43. **Rathkopf D.E., Beer T.M., Loriot Y., Higano C.S., Armstrong A.J., Sternberg C.N., de Bono J.S., Tombal B., Parli T., Bhattacharya S., Phung D., Krivoshik A., Scher H.I., and Morris M.J.** Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: The PREVAIL randomized clinical trial. [2018] *JAMA Oncology* (4) 5 : 694-701
44. **Recondo G., Facchinetti F., Olaussen K.A., Besse B., and Friboulet L.** Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? [2018] *Nature Reviews Clinical Oncology* (15) 11 : 694-708
45. **Robert C., Ribas A., Hamid O., Daud A., Wolchok J.D., Joshua A.M., Hwu W.J., Weber J.S., Gangadhar T.C., Joseph R.W., Dronca R., Patnaik A., Zarour H., Kefford R., Hersey P., Zhang J., Anderson J., Die-dre S.J., Ebbinghaus S., and Hodi F.S.** Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. [2018] *Journal of Clinical Oncology* (36) 17 : 1668-1674
46. **Routy B., Gopalakrishnan V., Daillere R., Zitvogel L., Wargo J.A., and Kroemer G.** The gut microbiota influences anti-cancer immunosurveillance and general health. [2018] *Nature Reviews Clinical Oncology* (15) 6 : 382-396
47. **Schoemaker M.J., [...], Boutron-Ruault M.C., [...], and Swerdlow A.J.** Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. [2018] *JAMA Oncology* (4) 11 : e181771
48. **Song X., Zhu S., Xie Y., Liu J., Sun L., Zeng D., Wang P., Ma X., Kroemer G., Bartlett D.L., Billiar T.R., Lotze M.T., Zeh H.J., Kang R., and Tang D.** JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. [2018] *Gastroenterology* (154) 5 : 1480-1493
49. **Strickler J.H., Weekes C.D., Nemunaitis J., Ramanathan R.K., Heist R.S., Morgensztern D., Angevin E., Bauer T.M., Yue H., Motwani M., Parikh A., Reilly E.B., Afar D., Naumovski L., and Kelly K.** First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. [2018] *Journal of Clinical Oncology* (36) 33 : 3298-3306
50. **Stringhini S., Carmeli C., Jokela M., Avendano M., McCrory C., d'Errico A., Bochud M., Barros H., Costa G., Chadeau-Hyam M., Delpierre C., Gandini M., Fraga S., Goldberg M., Giles G.G., Lassale C., Kenny R.A., Kelly-Irving M., Paccaud F., Layte R., Muennig P., Marmot M.G., Ribeiro A.I., Severi G., Steptoe A., Shipley M.J., Zins M., Mackenbach J.P., Vineis P., and Kivimaki M.** Socioeconomic status, non-communicable disease risk factors, and walking speed in older adults: multi-cohort population based study. [2018] *BMJ* (360) : k1046
51. **Subbiah V., Cabanillas M.E., Kreitman R.J., Wainberg Z.A., Cho J.Y., Keam B., Schellens J.H.M., Soria J.C., Wen P.Y., Zielinski C., Urbanowitz G., Mookerjee B., Wang D., and Rangwala F.** Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. [2018] *Journal of Clinical Oncology* (36) 1 : 7-13
52. **Tao Y., Auperin A., Sire C., Martin L., Khoury C., Maingon P., Bardet E., Kaminsky M.C., Lapeyre M., Chatellier T., Alfonsi M., Pointreau Y., Jadaud E., Gery B., Zawadi A., Tourani J.M., Laguerre B., Coutte A., Racadot S., Hasbini A., Maura-laurie E., Borel C., Meert N., Cornely A., Ollivier N., Casiraghi O., Sun X.S., and Bourhis J.** Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. [2018] *Journal of Clinical Oncology* (36) 31 : 3084-3090
53. **Tonorezos E.S., Barnea D., Cohn R.J., Cypriano M.S., Fresneau B.C., Haupt R., Hjorth L., Ishida Y., Kruseova J., Kuehni C.E., Kurkure P.A., Langer T., Nathan P.C., Skeen J.E., Skinner R., Tacyildiz N., Heuvel-Eibrink M.M., Winther J.F., Hudson M.M., and Oeffinger K.C.** Models of care for survivors of childhood cancer from across the globe: Advancing survivorship care in the next decade. [2018] *Journal of Clinical Oncology* (36) 21 : 2223-2230
54. **Toulmonde M., Penel N., Adam J., Chevreau C., Blay J.Y., Le Cesne A., Bom-pas E., Piperno-Neumann S., Cousin S., Grellety T., Ryckewaert T., Bessedé A., Ghinghelli F., Pulido M., and Italiano A.** Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas a phase 2 clinical trial. [2018] *JAMA Oncology* (4) 1 : 93-97
55. **Vaz-Luis I. and Partridge A.H.** Exogenous reproductive hormone use in breast cancer survivors and previvors. [2018] *Nature Reviews Clinical Oncology* (15) 4 : 249-261
56. **Walterhouse D.O., Barkauskas D.A., Hall D., Ferrari A., De Salvo G.L., Koscielniak E., Stevens M.C.G., Martelli H., Seitz G., Rodeberg D.A., Shnorhavorian M., Dasgupta R., Breneman J.C., Anderson J.R., Bergeron C., Bisogno G., Meyer W.H., Hawkins D.S., and Minard-Colin V.** Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. [2018] *Journal of Clinical Oncology* (36) 35 : 3466-3476
57. **Whelan J., Le Deley M.C., Dirksen U., Le Teuff G., Brennan B., Gaspar N., Hawkins D.S., Amler S., Bauer S., Bielack S., Blay J.Y., Burdach S., Castex M.P., Dilloo D., Eggert A., Gelderblom H., Gentet J.C., Hartmann W., Hassenpflug W.A., Hjorth L., Jimenez M., Klingebiel T., Kontny U., Kruseova J., Ladenstein R., Laurence V., Lervat C., Marec-Berard P., Marreaud S., Michon J., Morland B., Paulussen M., Ranft A., Reichardt P., van den Berg H., Wheatley K., Judson I., Lewis I., Craft A., Juergens H., Oberlin O., and Euro-E.W.I.N.G.99 and EWING-2008 Investigators.** High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. [2018] *Journal of Clinical Oncology* (36) 31 : 3110-3119
58. **Yoda S., Lin J.J., Lawrence M.S., Burke B.J., Friboulet L., Langenbucher A., Dardaie L., Prutisto-Chang K., Dagogo-Jack I., Timofeevski S., Hubbeling H., Gainor J.F., Ferris L.A., Riley A.K., Kattermann K.E., Timonina D., Heist R.S., Iafrate A.J., Benes C.H., Lennerz J.K., Mino-Kenudson M., Engelman J.A., Johnson T.W., Hata A.N., and Shaw A.T.** Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. [2018] *Cancer Discovery* (8) 6 : 714-729
59. **Zardavas D., Te Marvelde L., Milne R.L., Fumagalli D., Fountzilias G., Kotoula V., Razis E., Papaxoinis G., Joensuu H., Moynahan M.E., Hennessy B.T., Bieche I., Saal L.H., Stal O., Iacopetta B., Jensen J.D., O'Toole S., Lopez-Knowles E., Barbaraeschi M., Noguchi S., Azim H.A., Lerma E., Bachelot T., Wang Q., Perez-Tenorio G., Can de Velde C.J.H., Rea D.W., Sabine V., Bartlett J.M.S., Sotiriou C., Michiels S., and Loi S.** Tumor PIK3CA genotype and prognosis in early-stage breast cancer: A pooled analysis of individual patient data. [2018] *Journal of Clinical Oncology* (36) 10 : 981-990

Publications internationales Gustave Roussy 2018 avec impact factor 2017 compris entre 10 et 20 (hors congrès)

International publications Gustave Roussy 2018 with an impact factor 2017 between 10 and 20 (except meetings/poster abstracts)

1. **Abdellatif M., Sedej S., Carmona-Gutierrez D., Madeo F., and Kroemer G.** Autophagy in Cardiovascular Aging. [2018] *Circulation Research* (123) 7 : 803-824
2. **Abrahamo J., Silva L., Silva L.S., Khalil J.Y.B., Rodrigues R., Arantes T., Assis F., Boratto P., Andrade M., Kroon E.G., Ribeiro B., Bergier I., Seligmann H., Ghigo E., Colson P., Levasseur A., Kroemer G., Raoult D., and La Scola B.** Tailed giant Tupanvirus possesses the most complete translational apparatus of the known virosphere. [2018] *Nature Communications* (9) 1 : 749
3. **Adam J., Le Stang N., Rouquette I., Cazes A., Badoual C., Pinot-Roussel H., Tixier L., Danel C., Damiola F., Damotte D., Penault-Llorca F., and Lantuejoul S.** Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. [2018] *Annals of Oncology* (29) 4 : 953-958
4. **Adam J. and Postel-Vinay S.** Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups. [2018] *Annals of Oncology* (29) 4 : 798-799
5. **Andre F.** Annals of Oncology: factors for making a real impact. [2018] *Annals of Oncology* (29) 1 : 28-29
6. **Antoun S. and Raynard B.** Muscle protein anabolism in advanced cancer patients: response to protein and amino acids support, and to physical activity. [2018] *Annals of Oncology* (29) suppl 2 : ii10-ii17
7. **Armstrong A.J., Lin P., Higano C.S., Sternberg C.N., Sonpavde G., Tombal B., Templeton A.J., Fizazi K., Phung D., Wong E.K., Krivosikh A., and Beer T.M.** Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. [2018] *Annals of Oncology* (29) 11 : 2200-2207
8. **Armstrong A.J., Antonarakis E.S., Taplin M.E., Kelly W.K., Beltran H., Fizazi K., Dahut W.L., Shore N., Slovin S., George D., Carducci M.A., Corn P., Danila D., Dreicer R., Heath E., Rathkopf D., Liu G., Nanus D., Stein M., Smith M.R., Sternberg C., Wilding G., Nelson P.S., Halabi S., Kantoff P., Clarke N.W., Evans C.P., Heidenreich A., Mottet N., Gleave M., Morris M.J., and Scher H.I.** Naming disease states for clinical utility in prostate cancer: A rose by any other name might not smell as sweet. [2018] *Annals of Oncology* (29) 1 : 23-25
9. **Arnedos M., Bayar M.A., Cheaib B., Scott V., Bouakka I., Valent A., Adam J., Leroux-Kozal V., Marty V., Rapinat A., Mazouni C., Sarfati B., Bieche I., Balleyguier C., Gentien D., Delaloge S., Lacroix-Triki M., Michiels S., and Andre F.** Modulation of Rb phosphorylation and antiproliferative response to palbociclib. The Preoperative-Palbociclib (POP) randomized Clinical Trial. [2018] *Annals of Oncology* (29) 8 : 1755-1762
10. **Ascierto P.A. and Marabelle A.** How do immune checkpoint targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies. [2018] *Annals of Oncology* (29) 11 : 2157-2160
11. **Aspeshlagh S., Morel D., Soria J.C., and Postel-Vinay S.** Epigenetic modifiers as new immunomodulatory therapies in solid tumours. [2018] *Annals of Oncology* (29) 4 : 812-824
12. **Bachy E., Maurer M.J., Habermann T.M., Gelas-Dore B., Maucort-Boulch D., Estell J.A., Van den Neste E., Bouabdallah R., Gyan E., Feldman A.L., Bargay J., Delmer A., Slager S.L., da Silva M.G., Fitoussi O., Belada D., Maisonneuve H., Intragumtornchai T., Ansell S.M., Lamy T., Dartigues P., Link B.K., Seymour J.F., Cerhan J.R., and Salles G.** A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. [2018] *Blood* (132) 1 : 49-58
13. **Bady P., Kurscheid S., Delorenzi M., Goria T., van den Bent M.J., Hoang-Xuan K., Vauleon E., Gijtenbeek A., Enting R., Thiesen B., Chinot O., Dhermain F., Brandes A.A., Reijneveld J.C., Marosi C., Taphoorn M.J.B., Wick W., von Deimling A., French P., Stupp R., Baumert B.G., and Hegi M.E.** The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. [2018] *Acta Neuropathologica* (135) 4 : 601-615
14. **Banerjee S., Oza A.M., Birrer M.J., Hamilton E.P., Hasan J., Leary A., Moore K.N., Mackowiak-Matejczyk B., Pikiel J., Ray-Coquard I., Trask P., Lin K., Schuth E., Vaze A., Choi Y., Marsters J.C., Maslyar D.J., Lemahieu V., Wang Y., Humke E.W., and Liu J.F.** Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. [2018] *Annals of Oncology* (29) 4 : 917-923
15. **Baschieri F., Dayot S., Elkhatib N., Ly N., Capmany A., Schauer K., Betz T., Vignjevic D.M., Poincloux R., and Montagnac G.** Frustrated endocytosis controls contractility-independent mechanotransduction at clathrin-coated structures. [2018] *Nature communications* (9) 1 : 3825
16. **Bellanne-Chantelot C., Schmaltz-Panneau B., Marty C., Fenneteau O., Callebaut I., Clauin S., Docet A., Damaj G.L., Leblanc T., Pellier I., Stoven C., Souquere S., Antony-Debre I., Beaupain B., Aladjidi N., Barlogis V., Bauduer F., Bensaid P., Boespflug-Tanguy O., Berger C., Bertrand Y., Carausu L., Fieschi C., Galambrun C., Schmidt A., Journal H., Mazingue F., Nelken B., Quah T.C., Oksenhendler E., Ouachee M., Pasquet M., Saada V., Suarez F., Pierron G., Vainchenker W., Plo I., and Donadieu J.** Mutations in SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. [2018] *Blood* (132) 12 : 1318-1331
17. **Benitez-Guijarro M., Lopez-Ruiz C., Tarnauskait Z., Murina O., Mian Mohammad M., Williams T.C., Fluteau A., Sanchez L., Vilar-Astasio R., Garcia-Canadas M., Cano D., Kempen M.J.H.C., Sanchez-Pozo A., Heras S.R., Jackson A.P., Reijns M.A.M., and Garcia-Perez J.L.** RNase H2, mutated in Aicardi-Goutieres syndrome, promotes LINE-1 retrotransposition. [2018] *EMBO Journal* (37) 15 : UNSP e98506
18. **Berrou E., Soukaseum C., Favier R., Adam F., Elaib Z., Kauskot A., Bordet J.C., Ballerini P., Loyau S., Feng M., Dias K., Muheidli A., Girault S., Nurden A.T., Turro E., Ouwehand W.H., Denis C.V., Jandrot-Perrus**

- M., Rosa J.P., Nurden P., and Bryckaert M.** A mutation of the human EPHB2 gene leads to a major platelet functional defect. [2018] *Blood* (132) : 2067-2077
19. **Bertucci F., De Nonneville A., Finetti P., Perrot D., Nilbert M., Italiano A., Le Cesne A., Skubitz K.M., Blay J.Y., and Birnbaum D.** The genomic grade index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. [2018] *Annals of Oncology* (29) 2 : 459-466
20. **Bex A., Albiges L., Staehler M., Bensalah K., Giles R.H., Dabestani S., Hofmann F., Hora M., Kuczyk M.A., Lam T.B., Marconi L., Merseburger A.S., Fernandez-Pello S., Tahbaz R., Abu-Ghanem Y., Volpe A., Ljungberg B., Escudier B., and Powles T.** A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. [2018] *European Urology* (74) 6 : 849-851
21. **Bex A., Albiges L., Ljungberg B., Bensalah K., Dabestani S., Giles R.H., Hofmann F., Hora M., Kuczyk M.A., Lam T.B., Marconi L., Merseburger A.S., Fernandez-Pello S., Tahbaz R., Abu-Ghanem Y., Staehler M., Volpe A., and Powles T.** Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. [2018] *European Urology* (74) 6 : 805-809
22. **Bidard F.C., Michiels S., [...], and Pantel K.** Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. [2018] *Journal of the National Cancer Institute* (110) 6 : 560-567
23. **Bossi A.** Re: Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. [2018] *European Urology* (73) 4 : 637-638
24. **Bright C.J., [...], Allodji R.S., [...], and Reulen R.C.** Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe. [2018] *Journal of the National Cancer Institute* (110) 6 : 649-660
25. **Burgess S., [...], Clavel-Chapelon F., [...], and Riboli E.** Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A mendelian randomization analysis. [2018] *JAMA Cardiology* (3) 7 : 619-627
26. **Cardoso F., Senkus E., Costa A., Papadopoulos E., Aapro M., Andre F., Harbeck N., Aguilar L.B., Barrios C.H., Bergh J., Biganzoli L., Boers-Doets C.B., Cardoso M.J., Carey L.A., Cortes J., Curigliano G., Dieras V., El Saghir N.S., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Johnston S.R.D., Kaufman B., Koppikar S., Krop I.E., Mayer M., Nakigudde G., Offersen B.V., Ohno S., Pagani O., Paluch-Shimon S., Penault-Llorca F., Prat A., Rugo H.S., Sledge G.W., Spence D., Thomssen C., Vorobiof D.A., Xu B., Norton L., and Winer E.P.** 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). [2018] *Annals of Oncology* (29) 8 : 1634-1657
27. **Casali P.G., [...], Le Cesne A., [...], Blay J.Y., and ESMO Guidelines Committee and EURACAN.** Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. [2018] *Annals of Oncology* (29) suppl 4 : iv68-iv78
28. **Casali P.G., [...], Le Cesne A., [...], Blay J.Y., and ESMO Guidelines Committee and EURACAN.** Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. [2018] *Annals of Oncology* (29) suppl 4 : iv51-iv67
29. **Casali P.G., [...], Le Cesne A., [...], Blay J.Y., and ESMO Guidelines Committee, PaedCan and ERN EURACAN.** Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. [2018] *Annals of Oncology* (29) suppl 4 : iv79-iv95
30. **Cassard L., Sperber K., Buivan T.P., Cottillard A., Bourdet-Sicard R., Albert M.L., Mottez E., Laurent J., Guinépain M.T., and Daeron M.** Basophils from allergic patients are neither hyperresponsive to activation signals nor hyporesponsive to inhibition signals. [2018] *Journal of Allergy and Clinical Immunology* (142) 5 : 1548-1557
31. **Chanoine S., Pin I., Sanchez M., Temam S., Pison C., Le Moual N., Severi G., Boutron-Ruault M.C., Fournier A., Bousquet J., Bedouch P., Varraso R., and Siroux V.** Asthma Medication Ratio Phenotypes in Elderly Women. [2018] *Journal of Allergy and Clinical Immunology* (6) 3 : 897-906
32. **Chanoine S., Sanchez M., Pin I., Temam S., Le Moual N., Fournier A., Pison C., Bousquet J., Bedouch P., Boutron-Ruault M.C., Varraso R., and Siroux V.** Multimorbidity medications and poor asthma prognosis. [2018] *European Respiratory Journal* (51) 4 : 1702114
33. **Charpentier M., Khedher A.H.Y., Menoret S., Brion A., Lamribet K., Dardillac E., Boix C., Perrouault L., Tesson L., Geny S., De Cian A., Itier J.M., Anegon I., Lopez B., Giovannangeli C., and Concordet J.P.** CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair. [2018] *Nature Communications* (9) 1 : 1133
34. **Chicard M., Colmet-Daage L., Clement N., Danzon A., Bohec M., Bernard V., Baulande S., Bellini A., Deveau P., Pierron G., Lapouble E., Janoueix-Lerosey I., Peuchmaur M., Corradini N., Defachelles A.S., Valteau-Couanet D., Michon J., Combarret V., Delattre O., and Schleiermacher G.** Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. [2018] *Clinical Cancer Research* (24) 4 : 939-949
35. **Claret L., Jin J.Y., Ferte C., Winter H., Girish S., Stroh M., He P., Ballinger M., Sandler A., Joshi A., Rittmeyer A., Gandara D., Soria J.C., and Bruno R.** A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. [2018] *Clinical Cancer Research* (24) 14 : 3392-3298
36. **Colevas A.D., Bahleda R., Braiteh F., Balmanoukian A., Brana I., Chau N.G., Sarkar I., Molinero L., Grossman W., Kabbinnavar F., Fasso M., O'Hear C., and Powderly J.** Safety and Clinical Activity of Atezolizumab in Head and Neck Cancer: Results From a Phase I Trial. [2018] *Annals of Oncology* (29) 11 : 2247-2253
37. **Condorelli R., Spring L., O'Shaughnessy J., Lacroix L., Bailleux C., Scott V., Dubois J., Nagy R.J., Lanman R.B., Iafrate A.J., Andre F., and Bardia A.** Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. [2018] *Annals of Oncology* (29) 3 : 640-645
38. **Costantini A., Grynovska M., Lucibello F., Moises J., Pages F., Tsao M.S., Shepherd F.A., Bouchaab H., Garassino M., Aerts J.G.J.V., Mazieres J., Mondini M., Berghmans T., Meert A.P., and Cadranet J.** Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. [2018] *European Respiratory Journal* (51) 2 : 1702072
39. **Cottu P., D'Hondt V., Dureau S., Lerebours F., Desmoulins I., Heudel P.E., Duhoux F.P., Levy C., Mouret-Reynier M.A., Dalenc F., Frenel J.S., Jouannaud C., Venat-Bouvet L., Nguyen S., Ferrero J.M., Canon J.L., Grenier J., Callens C., Gentien D., Lemonnier J., Vincent-Salomon A., and Delaloge S.** Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. [2018] *Annals of Oncology* (29) 12 : 2334-2340
40. **Couronne L., Bachy E., Roulland S., Nadel B., Davi F., Armand M., Canioni D., Michot J.M., Visco C., Arcaini L., Besson C., and Hermine O.** From hepatitis C virus infection to B-cell lymphoma. [2018] *Annals of Oncology* (29) 1 : 92-100
41. **Couvain D., Bernheim A., Toffano-Nioche C., Touchon M., Michalik J., Neron B., Rocha E.P.C., Vergnaud G., Gautheret D., and Pourcel C.** CRISPRCasFinder, an update of CRISRFinder, includes a portable version, enhanced performance and integrates search for Cas proteins. [2018] *Nucleic Acids Research* (46) W1 : W246-W251
42. **Criscitello C., Bayar M.A., Curigliano G., Symmans F.W., Desmedt C., Bonnefoi H., Sinn B., Pruneri G., Vicier C., Pierga J.Y., Denkert C., Loibl S., Sotiriou C., Michiels S., and Andre F.** A gene signature to predict

high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. [2018] *Annals of Oncology* (29) 1 : 162-169

43. **de Boer S.M., Wortman B.G., Bosse T., Powell M.E., Singh N., Hollema H., Wilson G., Chowdhury M.N., Mileschkin L., Pym J., Katsaros D., Carinelli S., Fyles A., McLachlin C.M., Haie-Meder C., Duvillard P., Nout R.A., Verhoeven-Adema K.W., Putter H., Creutzberg C.L., Smit V.T.H.B., and for PORTEC Study Group.** Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. [2018] *Annals of Oncology* (29) 2 : 424-430

44. **de Bono J.S., Chowdhury S., Feyerabend S., Elliott T., Grande E., Melhem-Bertrandt A., Baron B., Hirmand M., Werbrouck P., and Fizazi K.** Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for \geq 24 weeks in Europe. [2018] *European Urology* (74) 1 : 37-45

45. **De Martin E., Michot J.M., Papouin B., Champiat S., Mateus C., Lambotte O., Roche B., Antonini T.M., Coilly A., Laghouati S., Robert C., Marabelle A., Guettier C., and Samuel D.** Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. [2018] *Journal of Hepatology* (68) 6 : 1181-1190

46. **De Martin E., Michot J.M., Papouin B., Champiat S., Lambotte O., Robert C., Marabelle A., Guettier C., and Samuel D.** Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". [2018] *Journal of Hepatology* (69) 6 : 1397-1398

47. **De Martin E., Michot J.M., Papouin B., Champiat S., Lambotte O., Robert C., Marabelle A., Guettier C., and Samuel D.** Reply to: "Mortality due to immunotherapy related hepatitis". [2018] *Journal of Hepatology* (69) 4 : 978-979

48. **De Martin E., Michot J.M., Champiat S., Lambotte O., Robert C., Marabelle A., Guettier C., and Samuel D.** Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". [2018] *Journal of Hepatology* (69) 2 : 550-551

49. **Depuydt P., Boeva V., Hocking T.D., Cannoodt R., Ambros I.M., Ambros P.F., Asgharzadeh S., Attiye E.F., Combaret V., Defferrari R., Fischer M., Hero B., Hogarty M.D., Irwin M.S., Koster J., Kreissman S., Ladenstein R., Lapouble E., Laureys G., London W.B., Mazzocco K., Nakagawara A., Noguera R., Ohira M., Park J.R., Potschger U., Theissen J., Tonini G.P., Valteau-Couanet D., Varesio L., Versteeg R., Speleman F., Maris J.M., Schleiermacher G., and De Preter K.** Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. [2018] *Journal of the National Cancer Institute* (110) 10 : 1084-1093

50. **Deretic V., Prossnitz E., Burge M., Campen M.J., Cannon J., Liu K.J., Sklar L.A., Allers L., Garcia S.A., Baehrecke E.H., Behrends C., Ceconi F., Codogno P., Chen G.C., Elazar Z., Eskelinen E.L., Fourie B., Gozuacik D., Hong W., Hotamisligi G., Jaattela M., Jo E.K., Johansen T., Juhasz G., Kimchi A., Ktistakis N., Kroemer G., Mizushima N., Munz C., Reggiori F., Rubinsztein D., Ryan K., Schroder K., Simonsen A., Tooze S., Vaccaro M., Yoshimori T., Yu L., Zhang H., and Klionsky D.J.** Autophagy, Inflammation, and Metabolism (AIM) Center of Biomedical Research Excellence: supporting the next generation of autophagy researchers and fostering international collaborations. [2018] *Autophagy* (14) 6 : 925-929

51. **Derosa L., Hellmann M.D., Spaziano M., Halpenny D., Fidelle M., Rizvi H., Long N., Plodkowski A.J., Arbour K.C., Chaft J.E., Arfi-Rouche J., Zitvogel L., Zalcman G., Albiges L., Escudier B., and Routy B.** Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. [2018] *Annals of Oncology* (29) 6 : 1437-1444

52. **Deschasaux M., [...], Boutron-Ruault M.C., [...], and Touvier M.** Nutritional quality of food as represented by the FSAm-NPS nutrient profiling system underlying the Nutri-Score label and cancer risk in Europe: Results from the EPIC prospective cohort study. [2018] *PLoS Medicine* (15) 9 : e1002651

53. **Dieci M.V., Radosevic-Robin N., Fineberg S., van den Eynden G., Ternes N., Penault-Llorca F., Pruneri G., D'Alfonso T.M., Demaria S., Castaneda C., Sanchez J., Badve S., Michiels S., Bossuyt V., Rojo F., Singh B., Nielsen T., Viale G., Kim S.R., Hewitt S., Wienert S., Loibl S., Rimm D., Symmans F., Denkert C., Adams S., Loi S., and Salgado R.** Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. [2018] *Seminars in Cancer Biology* (52) part 2 : 16-25

54. **Dogan S., Yamamoto-Ibusuki M., and Andre F.** Funding sources of practice-changing trials. [2018] *Annals of Oncology* (29) 4 : 1063-1065

55. **Drilon A., Lin J.J., Filleron T., Ni A., Milla J., Bergagnini I., Hatzoglou V., Velcheti V., Offin M., Li B., Carbone D.P., Besse B., Mok T., Awad M.M., Wolf J., Owen D., Cambridge D.R., Riely G.J., Peled N., Kris M.G., Mazieres J., Gainor J.F., and Gautschi O.** Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. [2018] *Journal of Thoracic Oncology* (13) 10 : 1595-1601

56. **du Vignaux C.M., Dansin E., Mhanna L., Greillier L., Pichon E., Kerjouan M., Clement-Duchene C., Mennecier B., Westeel V., Robert M., Quantin X., Zalcman G., Thiberville L., Lena H., Molina T., Calcagno**

F., Fournel P., Mazieres J., Besse B., and Girard N. Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. [2018] *Journal of Thoracic Oncology* (13) 11 : 1762-1770

57. **Dubsky P., [...], Andre F., [...], and Xu B.** Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. [2018] *Annals of Oncology* (29) 1 : 281-282

58. **Durand A., Audemard-Verger A., Guichard V., Mattiuz R., Delpoux A., Hamon P., Bonilla N., Riviere M., Delon J., Martin B., Auffray C., Boissonnas A., and Lucas B.** Profiling the lymphoid-resident T cell pool reveals modulation by age and microbiota. [2018] *Nature Communications* (9) 1 : 68

59. **Durgeau A., Virk Y., Gros G., Voilin E., Cognac S., Djenidi F., Salmon J., Adam J., de Montpreville V., Validire P., Ferrone S., Chouaib S., Eggermont A., Soria J.C., Lemonnier F., Tartour E., Chaput N., Besse B., and Mami-Chouaib F.** Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. [2018] *Nature Communications* (9) : 5097

60. **Escudier B. and Staehler M.** New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far? [2018] *European Urology* (73) 1 : 1-3

61. **Etienne H., Fabre D., Gomez C.A., Kolb F., Mussot S., Mercier O., Miltian D., Stephan F., Fadel E., and Darteville P.** Tracheal replacement. [2018] *European Respiratory Journal* (51) 2 : 1702211

62. **Fagherazzi G., El Fatouhi D., Fournier A., Gusto G., Mancini F.R., Balkau B., Boutron-Ruault M.C., Kurth T., and Bonnet F.** Associations Between Migraine and Type 2 Diabetes in Women: Findings From the E3N Cohort Study. [2018] *JAMA Neurology*

63. **Fanidi A., [...], Severi G., [...], and Johansson M.** Circulating Folate, Vitamin B6, and Methionine in Relation to Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3). [2018] *Journal of the National Cancer Institute* (110) 1 : 57-67

64. **Felip E., Barlesi F., Besse B., Chu Q., Gandhi L., Kim S.W., Carcereny E., Sequist L.V., Brunsvig P., Chouaid C., Smit E.F., Groen H.J.M., Kim D.W., Park K., Avsar E., Szpakowski S., Akimov M., and Garon E.B.** Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. [2018] *Journal of Thoracic Oncology* (13) 4 : 576-584

65. **Ferrara R., Mezquita L., and Besse B.** Progress in the Management of Advanced Thoracic Malignancies in 2017. [2018] *Journal of Thoracic Oncology* (13) 3 : 301-322

66. Ferrara R., Auger N., Auclin E., and Besse B. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. [2018] *Journal of Thoracic Oncology* (13) 1 : 27-45
67. Fidler M.M., Reulen R.C., Winter D.L., Allodji R.S., Bagnasco F., Bardi E., Bautz A., Bright C.J., Byrne J., Feijen E.A.M., Garwicz S., Grabow D., Gudmundsdottir T., Guha J., Haddy N., Jankovic M., Kaatsch P., Kaiser M., Kuonen R., Linge H., Maule M., Merletti F., Ofstaa H., Ronckers C.M., Skinner R., Teepen J., Terenziani M., Vu-Bezin G., Wesenberg F., Wiebe T., Jakab Z., Haupt R., Lahteenmaki P., Zaletel L.Z., Kuehni C.E., Winther J.F., de Vathaire F., Kremer L.C., Hjorth L., and Hawkins M.M. Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe. [2018] *Journal of the National Cancer Institute* (110) 2 : 183-194
68. Fossati N., Parker W.P., Karnes R.J., Colicchia M., Bossi A., Seisen T., Di Muzio N., Cozzarini C., Chiorda B.N., Fiorino C., Gandaglia G., Bartkowiak D., Wiegel T., Shariat S., Goldner G., Battaglia A., Joniau S., Haustermans K., De Meerleer G., Fonteyne V., Ost P., Van Poppel H., Montorsi F., Briganti A., and Boorjian S.A. More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. [2018] *European Urology* (74) 2 : 134-137
69. Fossati N., Karnes R.J., Colicchia M., Boorjian S.A., Bossi A., Seisen T., Di Muzio N., Cozzarini C., Noris Chiorda B., Fiorino C., Gandaglia G., Dell'Oglio P., Shariat S.F., Goldner G., Joniau S., Battaglia A., Haustermans K., De Meerleer G., Fonteyne V., Ost P., Van Poppel H., Wiegel T., Montorsi F., and Briganti A. Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. [2018] *European Urology* (73) 3 : 436-444
70. Frikha M., Auperin A., Tao Y., Elloumi F., Toumi N., Blanchard P., Lang P., Sun S., Racadot S., Thariat J., Alfonsi M., Tuchs C., Cornely A., Moussa A., Guigay J., Daoud J., and Bourhis J. A randomized trial of induction docetaxel-cisplatin- 5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma [GORTEC 2006-02]. [2018] *Annals of Oncology* (29) 3 : 731-736
71. Galluzzi L., Chan T.A., Kroemer G., Wolchok J.D., and Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. [2018] *Science Translational Medicine* (10) 459
72. Gandaglia G., Fossati N., Karnes R.J., Boorjian S.A., Colicchia M., Bossi A., Seisen T., Cozzarini C., Di Muzio N., Noris Chiorda B., Zaffuto E., Wiegel T., Shariat S.F., Goldner G., Joniau S., Battaglia A., Haustermans K., De Meerleer G., Fonteyne V., Ost P., Van Poppel H., Montorsi F., and Briganti A. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. [2018] *European Urology* (73) 4 : 512-518
73. Gaspar N., Marshall L.V., Binner D., Herold R., Rousseau R., Blanc P., Capdeville R., Carleer J., Copland C., Kerloeguen Y., Norga K., Pacaud L., Sevaux M.A., Spadoni C., Sterba J., Ligas F., Taube T., Uttenreuther-Fischer M., Chioato S., O'Connell M.A., Geoerger B., Blay J.Y., Soria J.C., Kaye S., Wulff B., Brugieres L., Vassal G., and Pearson A.D.J. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: Proposals from the multi-stakeholder platform-ACCELERATE. [2018] *Annals of Oncology* (29) 3 : 766-771
74. George D.J., Martini J.F., Staehler M., Motzer R.J., Magheli A., Escudier B., Gerletti P., Li S., Casey M., Laguerre B., Pandha H.S., Pantuck A.J., Patel A., Lechuga M.J., and Ravaud A. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. [2018] *Clinical Cancer Research* (24) 7 : 1554-1561
75. Geraud A., Mezquita L., Bigot F., Caramella C., Planchard D., Le Pechoux C., and Besse B. Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients. [2018] *Journal of Thoracic Oncology* (13) 11 : e215-e217
76. Geraud A., Mezquita L., Bigot F., Caramella C., Planchard D., Le Pechoux C., and Besse B. Long leptomeningeal responses with. [2018] *Journal of Thoracic Oncology* (13) 11 : e215-e217
77. Germini D., Tsfasman T., Zakharova V.V., Sjakste N., Lipinski M., and Vassetzky Y. A Comparison of Techniques to Evaluate the Effectiveness of Genome Editing. [2018] *Trends in Biotechnology* (36) 2 : 147-159
78. Ghez D., Calleja A., Protin C., Baron M., Ledoux M.P., Damaj G., Dupont M., Dreyfus B., Ferrant E., Herbaux C., Laribi K., Le Calloch R., Malphettes M., Paul F., Souchet L., Truchan-Graczyk M., Delavigne K., Dartigeas C., Ysebaert L., and French Innovative Leukemia Organization (FILO) CLL group Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. [2018] *Blood* (131) 17 : 1955-1959
79. Gillessen S., [...], Bossi A., [...], Fizazi K., [...], and Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. [2018] *European Urology* (73) 2 : 178-211
80. Glasner A., Levi A., Enk J., Isaacson B., Viukov S., Orlanski S., Scope A., Neuman T., Enk C.D., Hanna J.H., Sexl V., Jonjic S., Seliger B., Zitvogel L., and Mandelboim O. NKp46 Receptor-Mediated Interferon-gamma Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. [2018] *Immunity* (48) 1 : 107-119.e4
81. Goldman J.W., Noor Z.S., Remon J., Besse B., and Rosenfeld N. Are liquid biopsies a surrogate for tissue EGFR testing? [2018] *Annals of Oncology* (29) suppl 1 : i38-i46
82. Gomes-da-Silva L.C., Zhao L., Bezu L., Zhou H., Sauvat A., Liu P., Durand S., Leduc M., Souquere S., Loos F., Mondragon L., Sveinbjornsson B., Rekdal O., Boncompain G., Perez F., Arnaut L.G., Kepp O., and Kroemer G. Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. [2018] *EMBO Journal* (37) 13
83. Gravis G., Boher J.M., Chen Y.H., Liu G., Fizazi K., Carducci M.A., Oudard S., Joly F., Jarrard D.M., Soulie M., Eisenberger M.J., Habibi M., Dreicer R., Garcia J.A., Husain M.H.M., Kohli M., Vogelzang N.J., Picus J., DiPaola R., and Sweeney C. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHARTED and GETUG-AFU15 Studies. [2018] *European Urology* (73) 6 : 847-855
84. Guerrero-Zotano A.L., Stricker T.P., Formisano L., Hutchinson K.E., Stover D.G., Lee K.M., Schwarz L.J., Giltneane J.M., Estrada M.V., Jansen V.M., Servetto A., Gavila J., Alejandro J.P.F., Lluch A., Llombart-Cusac A., Bayar M.A., Michiels S., Andre F., Arnedos M., Guillem V., Ruiz-Simon A., and Arteaga C.L. ERb Breast cancers resistant to prolonged neoadjuvant letrozole exhibit an e2f4 transcriptional program sensitive to cdk4/6 inhibitors. [2018] *Clinical Cancer Research* (24) 11 : 2517-2529
85. Gujar S., Pol J.G., Kim Y., Lee P.W., and Kroemer G. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. [2018] *Trends in Immunology* (39) 3 : 209-221
86. Hansen A.R., Massard C., Ott P.A., Haas N.B., Lopez J.S., Ejadi S., Wallmark J.M., Keam B., Delord J.P., Aggarwal R., Gould M., Yang P., Keefe S.M., and Piha-Paul S.A. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. [2018] *Annals of Oncology* (29) 8 : 1807-1813
87. Hidalgo M., Martinez-Garcia M., Le Tourneau C., Massard C., Garralda E., Boni V., Taus A., Albanell J., Sablin M.P., Alt M., Bahleda R., Varga A., Boetsch C., Franjkovic I., Heil F., Lahr A., Lechner K., Morel A., Nayak T., Rossomanno S., Smart K., Stubenrauch K., and Krieter O. First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-vegf-a antibody, in adult patients with advanced solid tumors. [2018] *Clinical Cancer Research* (24) 7 : 1536-1545
88. Hofmann I., Geer M.J., Vogtle T., Crispin A., Campagna D.R., Barr A., Calicchio M.L., Heising S., Van Geffen J.P., Kuijpers M.J.E.,

- Heemskerk J.W.M., Eble J.A., Schmitz-Abe K., Obeng E.A., Douglas M., Freson K., Pondarre C., Favier R., Jarvis G.E., Markianos K., Turro E., Ouwehand W.H., Mazharian A., Fleming M.D., and Senis Y.A. Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice. [2018] *Blood* (132) 13 : 1399-1412
89. Honecker F., [...], Fizazi K., [...], and Horwich A. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. [2018] *Annals of Oncology* (29) 8 : 1658-1686
90. Hooks K.B., Audoux J., Fazli H., Lesjean S., Ernault T., Dugot-Senant N., Leste-Lasserre T., Hagedorn M., Rousseau B., Danet C., Branchereau S., Brugieres L., Taqea S., Guettier C., Fabre M., Rullier A., Buendia M.A., Commes T., Grosset C.F., and Raymond A.A. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. [2018] *Hepatology* (68) 1 : 89-102
91. Italiano A., Infante J.R., Shapiro G.I., Moore K.N., LoRusso P.M., Hamilton E., Cousin S., Toulmonde M., Postel-Vinay S., Tolaney S., Blackwood E.M., Mahrus S., Peale F.V., Lu X., Moein A., Epler J., DuPree K., Tagen M., Murray E.R., Schutzman J.L., Lauchle J.O., Hollebecq A., and Soria J.C. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. [2018] *Annals of Oncology* (29) 5 : 1304-1311
92. Itzykson R., Duployez N., Fasan A., Decool G., Marceau-Renaut A., Megendorfer M., Jourdan E., Petit A., Lapillonne H., Micol J.B., Cornillet-Lefebvre P., Ifrah N., Leverger G., Dombret H., Boissel N., Hafnerlach T., and Preudhomme C. Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia. [2018] *Blood* (132) 2 : 187-196
93. Jacquilot N., Zitvogel L., and Eggermont A.M. Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'. [2018] *Nature Communications* (9) 1 : 2922
94. Joseph R.W., Elassaiss-Schaap J., Kefford R.F., Hwu W.J., Wolchok J.D., Joshua A.M., Ribas A., Hodi F.S., Hamid O., Robert C., Daud A.I., Dronca R.S., Hersey P., Weber J.S., Patnaik A., de Alwis D.P., Perrone A.M., Zhang J., Kang S.P., Ebbinghaus S.W., Anderson K.M., and Gangadhar T. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab. [2018] *Clinical Cancer Research* (24) 20 : 4960-4967
95. Jurisic A., Robin C., Tarkov P., Siggens L., Schoell B., Jauch A., Ekwall K., SÅrensen C.S., Lipinski M., Shoaib M., and Ogrzyzko V. Topokaryotyping demonstrates single cell variability and stress dependent variations in nuclear envelope associated domains. [2018] *Nucleic Acids Research* (46) 22 : e135
96. Kang R., Zeng L., Zhu S., Xie Y., Liu J., Wen Q., Cao L., Xie M., Ran Q., Kroemer G., Wang H., Billiar T.R., Jiang J., and Tang D. Lipid Peroxidation Drives Gasdermin D-Mediated Pyroptosis in Lethal Polymicrobial Sepsis. [2018] *Cell Host and Microbe* (24) 1 : 97-108.e4
97. Klauschen F., [...], Michiels S., [...], Denkert C., and on behalf of the International Immuno-Oncology Biomarker Working Group Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. [2018] *Seminars in Cancer Biology* (52) part 2 : 151-157
98. Klein A.P., [...], Severi G., [...], and Amundadottir L.T. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. [2018] *Nature Communications* (9) : 556
99. Koubi M., Poplineau M., Vernerey J., N'Guyen L., Tiberi G., Garciaz S., El-Kaoutari A., Maqbool M.A., Andrau J.C., Guillouf C., Saurin A.J., and Duprez E. Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity. [2018] *Nucleic Acids Research* (46) 7 : 3339-3350
100. Krug A.K., Enderle D., Karlovich C., Priewasser T., Bentink S., Spiel A., Brinkmann K., Emenegger J., Grimm D.G., Castellanos-Rizaldos E., Goldman J.W., Sequist L.V., Soria J.C., Camidge D.R., Gadgeel S.M., Wakelee H.A., Raponi M., Noerholm M., and Skog J. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. [2018] *Annals of Oncology* (29) 10 : 2143
101. Krug A.K., Enderle D., Karlovich C., Priewasser T., Bentink S., Spiel A., Brinkmann K., Emenegger J., Grimm D.G., Castellanos-Rizaldos E., Goldman J.W., Sequist L.V., Soria J.C., Camidge D.R., Gadgeel S.M., Wakelee H.A., Raponi M., Noerholm M., and Skog J. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. [2018] *Annals of Oncology* (29) 3 : 700-706
102. Lavaud P., Gravis G., Foulon S., Joly F., Oudard S., Priou F., Latorzeff I., Mourey L., Soulie M., Delva R., Krakowski I., Laguerre B., Theodore C., Ferrero J.M., Beuzeboc P., Habibian M., Roland F., Deplanque G., Pouessel D., Zanetta S., Berdah J.F., Dauba J., Baciuchka M., Platini C., Linossier C., Tubiana-Mathieu N., Machiels J.P., Kouri C.E., Ravaud A., Suc E., Eymard J.C., Hasbini A., Bousquet G., Culine S., Boher J.M., Tergemina-Clain G., Legoupil C., and Fizazi K. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. [2018] *European Urology* (73) 5 : 696-703
103. Le Burel S., Champiat S., Routier E., Aspeslagh S., Albiges L., Szwebel T.A., Michot J.M., Chretien P., Mariette X., Voisin A.L., and Lambotte O. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. [2018] *Annals of the Rheumatic Diseases* (77) 3 : 468-470
104. Lebeau C., Vallee D., Rousseau D., Patouraux S., Bonnafous S., Adam G., Luciano F., Luci C., Anty R., Iannelli A., Marchetti S., Kroemer G., Lacas-Gervais S., Tran A., Gual P., and Bailly-Maitre B. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice. [2018] *Hepatology* (68) 2 : 515-532
105. Leboulloux S., Borget I., and Schlumberger M. Radioactive iodine ablation in low-risk thyroid cancer - Authors' reply. [2018] *Lancet Diabetes and Endocrinology* (6) 9 : 686-687
106. Leman R., Gaildrat P., Gac G.L., Ka C., Fichou Y., Audrezet M.P., Caux-Moncoutier V., Caputo S.M., Boutry-Kryza N., Leone M., Mazoyer S., Bonnet-Dorion F., Sevenet N., Guillaud-Bataille M., Rouleau E., Bressac-de P.B., Wappenschmidt B., Rossing M., Muller D., Bourdon V., Revillon F., Parsons M.T., Rousselin A., Davy G., Castelain G., Castera L., Sokolowska J., Coulet F., Delnatte C., Ferec C., Spurdle A.B., Martins A., Krieger S., and Houdayer C. Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort. [2018] *Nucleic Acids Research* (46) 15 : 7913-7923
107. Lenglet M., [...], Richard S., [...], and Gardie B. Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. [2018] *Blood* (132) 5 : 469-483
108. Levy A., Hendriks L.E., and Faivre-Finn C. Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients? [2018] *Journal of Thoracic Oncology* (13) 4 : 475-477
109. Lin W., Yip Y.L., Jia L., Deng W., Zheng H., Dai W., Ko J.M.Y., Lo K.W., Chung G.T.Y., Yip K.Y., Lee S.D., Kwan J.S., Zhang J., Liu T., Chan J.Y., Kwong D.L., Lee V.H., Nicholls J.M., Busson P., Liu X., Chiang A.K.S., Hui K.F., Kwok H., Cheung S.T., Cheung Y.C., Chan C.K., Li B., Cheung A.L., Hau P.M., Zhou Y., Tsang C.M., Middeldorp J., Chen H., Lung M.L., and Tsao S.W. Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. [2018] *Nature Communications* (9) 1 : 4663
110. Little M.P., Wakeford R., Borrego D., French B., Zablotska L.B., Adams M.J., Alldredge R., de Vathaire F., Lee C., Brenner A.V., Miller J.S., Campbell D., Pearce M.S., Doody M.M., Holmberg E., Lundell M., Sadetzki S., Linet M.S., and Berrington de G.A. Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies. [2018] *Lancet Hematology* (5) 8 : e346-e358

111. Louvel G., Bahleda R., Ammari S., Le Pechoux C., Levy A., Massard C., Le Pavec J., Champiat S., and Deutsch E. Immuno-therapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis? [2018] *European Respiratory Journal* (51) 1 : 1701737
112. Luis Perez-Gracia J., Lorient Y., Rosenberg J.E., Powles T., Necchi A., Hussain S.A., Morales-Barrera R., Retz M.M., Niegisch G., Duran I., Theodore C., Grande E., Shen X., Wang J., Nelson B., Derleth C.L., and van der Heijden M.S. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. [2018] *European Urology* (73) 3 : 462-468
113. Machiela M.J., [...], Gaspar N., [...], and Delattre O. Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. [2018] *Nature Communications* (9) 1 : 3184
114. Malcov-Brog H., Alpert A., Golan T., Parikh S., Nordlinger A., Netti F., Sheinboim D., Dror I., Thomas L., Cosson C., Gonen P., Stanevsky Y., Brenner R., Perluk T., Frand J., Elgavish S., Nevo Y., Rahat D., Tabach Y., Khaled M., Shen-Orr S.S., and Levy C. UV-Protection Timer Controls Linkage between Stress and Pigmentation Skin Protection Systems. [2018] *Molecular Cell* (72) 3 : 444-456.e7
115. Marabelle A., Andtbacka R., Harrington K., Melero I., Leidner R., de Baere T., Robert C., Ascierto P.A., Baurain J.F., Imperiale M., Rahimian S., Tersago D., Klumper E., Hendriks M., Kumar R., Stern M., Ohrling K., Massacesi C., Tchakov I., Tse A., Douillard J.Y., Tabernero J., Haanen J., and Brody J. Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT). [2018] *Annals of Oncology* (29) 11 : 2163-2174
116. Marchant N.L., Barnhofer T., Klimecki O.M., Poisnel G., Lutz A., Arenaza-Urquijo E., Collette F., Wirth M., Schild A.K., Coll-Padros N., Reyrolle L., Horney D., Krolak-Salmon P., Molinuevo J.L., Walker Z., Maillard A., Frison E., Jessen F., and Chetelat G. The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). [2018] *Alzheimer's & Dementia* (4) : 737-745
117. Marisa L., Svrcek M., Collura A., Becht E., Cervera P., Wanherdrick K., Buhard O., Goloudina A., Jonchere V., Selves J., Milano G., Guenet D., Cohen R., Colas C., Laurent-Puig P., Olschwang S., Lefevre J.H., Parc Y., Boige V., Lepage C., Andre T., Flejou J.F., Derangere V., Ghiringhelli F., de Reynies A., and Duval A. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. [2018] *Journal of the National Cancer Institute* (110) 1 : 68-77
118. Massard C., Azaro A., Soria J.C., Lassen U., Le Tourneau C., Sarker D., Smith C., Ohnmacht U., Oakley G., Patel B.K.R., Yuen E.S.M., Benhadji K.A., and Rodon J. First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer. [2018] *Annals of Oncology* (29) 9 : 1911-1917
119. Mateo J., Chakravarty D., Dienstmann R., Jezdic S., Gonzalez-Perez A., Lopez-Bigas N., Ng C.K.Y., Bedard P.L., Tortora G., Douillard J.Y., Van Allen E.M., Schultz N., Swanton C., Andre F., and Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). [2018] *Annals of Oncology* (29) 9 : 1895-1902
120. Mauge L., Mejean A., Fournier L., Pereira H., Etienne-Grimaldi M.C., Levionnois E., Caty A., Abadie-Lacourtoisie S., Culine S., Le Moulec S., Linossier C., Theodore C., Ravaut A., Albiges L., Grine A., Tatour E., Milano G., Gille A.S., Verkarre V., Helley D., and Oudard S.M. Sunitinib prior to planned nephrectomy in metastatic renal cell carcinoma: angiogenesis biomarkers predict clinical outcome in the prospective Phase 2 PREINSUT trial. [2018] *Clinical Cancer Research* (24) 22 : 5534-5542
121. Mehra N., Dolling D., Sumanasuriya S., Christova R., Pope L., Carreira S., Seed G., Yuan W., Goodall J., Hall E., Flohr P., Boysen G., Bianchini D., Sartor O., Eisenberger M.A., Fizazi K., Oudard S., Chadja M., Mace S., and de Bono J.S. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). [2018] *European Urology* (74) 3 : 283-291
122. Meidtner K., [...], Fagherazzi G., [...] and Wareham N.J. Interaction of Dietary and Genetic Factors Influencing Body Iron Status and Risk of Type 2 Diabetes Within the EPIC-InterAct Study. [2018] *Diabetes Care* (41) 2 : 277-285
123. Mendez-Bermudez A., Lototska L., Bauwens S., Giraud-Panis M.J., Croce O., Jamet K., Irizar A., Mowinkel M., Koundrioukoff S., Nottet N., Almouzni G., Teulade-Fichou M.P., Schertzer M., Perderiset M., Londono-Vallejo A., Debatisse M., Gilson E., and Ye J. Genome-wide Control of Heterochromatin Replication by the Telomere Capping Protein TRF2. [2018] *Molecular Cell* (70) 3 : 449-461
124. Meyer G., Besse B., Doubre H., Charles-Nelson A., Aquilanti S., Izadifar A., Azarian R., Monnet I., Lamour C., Descourt R., Oliviero G., Taillade L., Chouaid C., Giraud F., Falcoz P.E., Revel M.P., Westeel V., Dixmier A., Tredaniel J., Dehette S., Desrossette C., Prevost A., Pichon E., Fabre E., Soria J.C., Friard S., Stern J.B., Jabot L., Dennewald G., Pavy G., Petitpretz P., Tourani J.M., Alifano M., Chatellier G., and Girard P. Anti-tumour effect of low molecular weight heparin in localised lung cancer: A phase III clinical trial. [2018] *European Respiratory Journal* (52) 4 : 1801220
125. Meziani L., Mondini M., Petit B., Boissonnas A., De Montpreville V.T., Mercier O., Vozenin M.C., and Deutsch E. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. [2018] *European Respiratory Journal* (51) 3 : 170212
126. Michiels S. and Delaloge S. All simulation models of breast cancer are wrong but some are useful. [2018] *Lancet Global Health* (6) 8 : e818-e819
127. Michot J.M., Pruvost R., Mateus C., Champiat S., Voisin A.L., Marabelle A., and Lambotte O. Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. [2018] *Annals of Oncology* (29) 2 : 518-520
128. Mir O., Ropert S., Chamseddine A., and Paci A. Curcumin dietary supplements and everolimus-based cancer treatment. [2018] *Annals of Oncology* (29) 1 : 287-288
129. Motzer R.J., Ravaut A., Patard J.J., Pandha H.S., George D.J., Patel A., Chang Y.H., Escudier B., Donskov F., Magheli A., Carteni G., Laguerre B., Tomczak P., Breza J., Gerletti P., Lechuga M., Lin X., Casey M., Serfass L., Pantuck A.J., and Staehler M. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. [2018] *European Urology* (73) 1 : 62-68
130. Motzer R.J., Escudier B., and Ravaut A. Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzone's Letter to the Editor re: Robert J. Motzer, Alain Ravaut, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. *Eur Urol* 2018; 73:62-8. [2018] *European urology* (73) 3 : E73-E73
131. Muller D.C., [...], Severi G., [...], and Brennan P. No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3). [2018] *Annals of Oncology* (29) 6 : 1468-1475
132. Nemoz C., Ropars V., Frit P., Gontier A., Drevet P., Yu J., Guerois R., Pitois A., Comte A., Delteil C., Barboule N., Legrand P., Baccannais S., Yin Y., Tadi S., Barbet-Massin E., Berger I., Le Cam E., Modesti M., Rothenberg E., Calsou P., and Charbonnier J.B. XLF and APLF bind Ku80 at two remote sites to ensure DNA repair by non-homologous end joining. [2018] *Nature Structural & Molecular Biology* (25) 10 : 971-980
133. Neuzillet C., de Mestier L., Rousseau B., Mir O., Hebbar M., Kocher H.M., Ruzsniowski P., and Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma,

- and gastro-intestinal stromal tumours. [2018] *Pharmacology & Therapeutics* (181) : 49-75
134. **Oberkampff M., Guillerey C., Mouries J., Rosenbaum P., Fayolle C., Bobard A., Savina A., Ogier-Denis E., Enninga J., Amigorena S., Leclerc C., and Dadaglio G.** Mitochondrial reactive oxygen species regulate the induction of CD8+ T cells by plasmacytoid dendritic cells. [2018] *Nature Communications* (9) 1 : 2241
135. **Obrist F., Michels J., Durand S., Chery A., Pol J., Levesque S., Joseph A., Astesana V., Pietrocola F., Wu G.S., Castedo M., and Kroemer G.** Metabolic vulnerability of cisplatin-resistant cancers. [2018] *EMBO Journal* (37) 14 : e98597
136. **Paoletti X. and Postel-Vinay S.** Phase I-II trial designs: how early should efficacy guide the dose recommendation process? [2018] *Annals of Oncology* (29) 3 : 540-541
137. **Pentzold C., Shah S.A., Hansen N.R., Le Tallec B., Seguin-Orlando A., Debatisse M., Lisby M., and Oestergaard V.H.** FANCD2 binding identifies conserved fragile sites at large transcribed genes in avian cells. [2018] *Nucleic Acids Research* (46) 3 : 1280-1294
138. **Pierron G. and Weil D.** Re-viewing the 3D Organization of mRNPs. [2018] *Molecular Cell* (72) 4 : 603-605
139. **Pietrocola F., Castoldi F., Maiuri M.C., and Kroemer G.** Aspirin-another caloric-restriction mimetic. [2018] *Autophagy* (14) 7 : 1162-1163
140. **Planchard D., Popat S., Kerr K., Novello S., Smit E.F., Faivre-Finn C., Mok T.S., Reck M., Van Schil P.E., Hellmann M.D., Peters S., and ESMO Guidelines Committee.** Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [2018] *Annals of Oncology* (29) suppl 4 : iv192-iv237
141. **Poisnel G., Arenaza-Urquijo E., Collette F., Klimecki O.M., Marchant N.L., Wirth M., de La Sayette V., Rauchs G., Salmon E., Vuilleumier P., Frison E., Maillard A., Vivien D., Lutz A., Chetelat G., and Medit-Ageing Research Group.** The Age-Well randomized controlled trial of the Medit-Ageing European project: Effect of meditation or foreign language training on brain and mental health in older adults. [2018] *Alzheimer's & Dementia* (4) : 714-723
142. **Poisson J., Hilscher M.B., Tanguy M., Hammoutene A., Boulanger C.M., Villeval J.L., Simonetto D.A., Valla D., Shah V.H., and Rautou P.E.** Endothelial JAK2(V617F) does not enhance liver lesions in mice with Budd-Chiari syndrome. [2018] *Journal of Hepatology* (68) 5 : 1086-1087
143. **Pol J. and Kroemer G.** Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy. [2018] *Cell Research* (28) 5 : 501-502
144. **Porporato P.E., Filigheddu N., Pedro J.M.B., Kroemer G., and Galluzzi L.** Mitochondrial metabolism and cancer. [2018] *Cell Research* (28) 3 : 265-280
145. **Powles T., Albiges L., Staehler M., Bensalah K., Dabestani S., Giles R.H., Hofmann F., Hora M., Kuczyk M.A., Lam T.B., Marconi L., Merseburger A.S., Fernandez-Pello S., Tahbaz R., Volpe A., Ljungberg B., and Bex A.** Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. [2018] *European Urology* (73) 3 : 311-315
146. **Ray-Coquard I., Morice P., Lorusso D., Prat J., Oaknin A., Pautier P., and Colombo N.** Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [2018] *Annals of Oncology* (29) suppl 4 : iv1-iv18
147. **Ricordel C., Friboulet L., Facchinetti F., and Soria J.C.** Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. [2018] *Annals of Oncology* (29) suppl 1 : i28-i37
148. **Rini B.I., Escudier B., Martini J.F., Magheli A., Svedman C., Lopatin M., Knezevic D., Goddard A.D., Febbo P.G., Li R., Lin X., Valota O., Staehler M., Motzer R.J., and Ravaud A.** Validation of the 16-Gene Recurrence Score in patients with locoregional, high-risk renal cell carcinoma from a phase 3 trial of adjuvant sunitinib. [2018] *Clinical Cancer Research* (24) 18 : 4407-4415
149. **Rochat T., Bohn C., Morvan C., Le Lam T.N., Razvi F., Pain A., Toffano-Nioche C., Ponien P., Jacq A., Jacquet E., Fey P.D., Gautheret D., and Bouloc P.** The conserved regulatory RNA RsaE down-regulates the arginine degradation pathway in *Staphylococcus aureus*. [2018] *Nucleic Acids Research* (46) 17 : 8803-8816
150. **Rugo H.S., Delord J.P., Im S.A., Ott P.A., Piha-Paul S.A., Bedard P.L., Sachdev J., Tourneau C.L., van Brummelen E.M.J., Varga A., Salgado R., Loi S., Saraf S., Pietrangelo D., Karantza V., and Tan A.R.** Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. [2018] *Clinical Cancer Research* (24) 12 : 2804-2811
151. **Rybstein M.D., Bravo-San Pedro J.M., Kroemer G., and Galluzzi L.** The autophagic network and cancer. [2018] *Nature Cell Biology* (20) 3 : 243-251
152. **Scelo G., Muller D.C., Riboli E., Johansson M., Cross A.J., Vineis P., Tsilidis K.K., Brennan P., Boeing H., Peters P.H., Vermeulen R., Overvad K., Bueno-de-Mesquita B., Severi G., Perduca V., Kvaskoff M., Trichopoulou A., La Vecchia C., Karakatsani A., Palli D., Sieri S., Panico S., Weiderpass E., Sandanger T.M., Nost T.H., Agudo A., Quiros J.R., Rodriguez-Barranco M., Chirlaque M.D., Key T.J., Khanna P., Bonventre J.V., Sabbisetti V.S., and Bhatt R.S.** KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study. [2018] *Clinical Cancer Research* (24) 22 : 5594-5601
153. **Schlumberger M., Leboulleux S., Cactargi B., Deandreis D., Zerdoud S., Bardet S., Rusu D., Godbert Y., Buffet C., Schwartz C., Vera P., Morel O., Benisvy D., Bournaud C., Toubert M.E., Kelly A., Benhamou E., and Borget I.** Outcome after ablation in patients with low-risk thyroid cancer (ES-TIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. [2018] *Lancet Diabetes and Endocrinology* (6) 8 : 618-626
154. **Schoffski P., Wozniak A., Kasper B., Aamdal S., Leahy M.G., Rutkowski P., Bauer S., Gelderblom H., Italiano A., Lindner L.H., Hennig I., Strauss S., Zakotnik B., Anthony A., Albiges L., Blay J.Y., Reichardt P., Sufliarsky J., van der Graaf W.T.A., Debiec-Rychter M., Sciort R., Van Cann T., Marreud S., Raveloarivahy T., Collette S., and Stacchiotti S.** Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'. [2018] *Annals of Oncology* (29) 3 : 758-765
155. **Schuurhuizen C.S.E.W., Marino P., Braamse A.M.J., Buffart L.M., Joly F., Fizazi K., Habibian M., Boher J.M., Soulie M., Oudard S., Konings I.R.H.M., Verheul H.M.W., Dekker J., and Gravis G.** Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer. [2018] *Journal of the National Comprehensive Cancer Network : JNCCN*. (16) 12 : 1481-1488
156. **Scotte F., Bossi P., Carola E., Cudennec T., Dielenseger P., Gomes F., Knox S., and Strasser F.** Addressing the quality of life needs of older patients with cancer: A SIOG consensus paper and practical guide. [2018] *Annals of Oncology* (29) 8 : 1718-1726
157. **Selimoglu-Buet D., Riviere J., Ghamlouch H., Bencheikh L., Lacout C., Morabito M., Diop M., Meurice G., Breckler M., Chauveau A., Debord C., Debeurme F., Itzykson R., Chapuis N., Willekens C., Wagner-Ballon O., Bernard O.A., Droin N., and Solary E.** A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset. [2018] *Nature Communications* (9) 1 : 5455
158. **Sevin M., Kubovcakova L., Pernet N., Causse S., Vitte F., Villeval J.L., Lacout C., Cordonnier M., Rodrigues-Lima F., Chanteloup G., Mosca M., Chretien M.L., Bastie J.N., Audia S., Sagot P., Ramla S., Martin L., Gleave M., Mezger V., Skoda R., Plo I., Garrido C., Girodon F., and De Thonel A.** HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. [2018] *Nature Communications* (9) 1 : 1431

159. Sica V. and Kroemer G. IMMP2L: A mitochondrial protease suppressing cellular senescence. [2018] *Cell Research* (28) 6 : 607-608
160. Smoragiewicz M., Bogaerts J., Calvo E., Marabelle A., Perrone A., Seymour L., Shalabi A., Siu L.L., Tabertero J., and Giaccone G. Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. [2018] *Annals of Oncology* (29) 11 : 2175-2182
161. Sobhani I., Itti E., Luciani A., Baumgaertner I., Layese R., Andre T., Ducreux M., Gornet J.M., Goujon G., Aparicio T., Taieb J., Bachet J.B., Hemery F., Retbi A., Mons M., Flicoteaux R., Rhein B., Baron S., Cherrak I., Rufat P., Le Corvoisier P., de'Angelis N., Natella P.A., Maoulida H., Tournigand C., Durand Zaleski I., and Bastuji-Garin S. Colorectal cancer (CRC) monitoring by 6-monthly 18F-FDG-PET/CT: An open-label multicentre randomised trial. [2018] *Annals of Oncology* (29) 4 : 931-937
162. Soria J.C., Ho S.N., Varella-Garcia M., Iafrate A.J., Solomon B.J., Shaw A.T., Blackhall F., Mok T.S., Wu Y.L., Pestova K., Wilner K.D., Polli A., Paolini J., Lanzalone S., Green S., and Camidge D.R. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. [2018] *Annals of Oncology* (29) 9 : 1964-1971
163. Soularue E., Lepage P., Colombel J.F., Coutzac C., Faleck D., Marthey L., Collins M., Chaput N., Robert C., and Carbone F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. [2018] *Gut* (67) : 2056-2067
164. Staehler M., Motzer R.J., George D.J., Pandha H.S., Donskov F., Escudier B., Pantuck A.J., Patel A., DeAnnuntis L., Bhattacharyya H., Ramaswamy K., Zanotti G., Lin X., Lechuga M., Serfass L., Paty J., and Ravaud A. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. [2018] *Annals of Oncology* (29) 10 : 2098-2104
165. Stathis A., Iasonos A., Seymour J.F., Thieblemont C., Ribrag V., Zucca E., and Younes A. Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas. [2018] *Clinical Cancer Research* (24) 13 : 2993-2998
166. Stein E.M., DiNardo C.D., Fathi A.T., Pollyea D.A., Stone R.M., Altman J.K., Roboz G.J., Patel M.R., Collins R., Flinn I.W., Sekeres M.A., Stein A.S., Kantarjian H.M., Levine R.L., Vyas P., MacBeth K.J., Tosolini A., VanOostendorp J., Xu Q., Gupta I., Lila T., Risueño A., Yen K.E., Wu B., Attar E.C., Tallman M.S., and de Botton S. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. [2018] *Blood* epub dec. 3
167. Stiefel F., Kiss A., Salmon P., Peters S., Razavi D., Cervantes A., Margulies A., Bourquin C., Dauchy S., Entwistle V., Grassi L., Jermann P., Langewitz W., Margulies A., Salander P., Smets E., Sollner W., and Zulfian G. Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018. [2018] *Annals of Oncology* (29) 10 : 2033-2036
168. Suciu S., Eggermont A.M.M., Lorigan P., Kirkwood J.M., Markovic S.N., Garbe C., Cameron D., Kotapati S., Chen T.T., Wheatley K., Ives N., De Schaetzen G., Efendi A., and Buyse M. Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy. [2018] *Journal of the National Cancer Institute* (110) 1 : 87-96
169. Sun M., Marconi L., Eisen T., Escudier B., Giles R.H., Haas N.B., Harshman L.C., Quinn D.I., Larkin J., Pal S.K., Powles T., Ryan C.W., Sternberg C.N., Uzzo R., Choueiri T.K., and Bex A. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. [2018] *European Urology* (74) 5 : 611-620
170. Swain S.M., Ewer M.S., Viale G., Delaloge S., Ferrero J.M., Verrill M., Colomer R., Vieira C., Werner T.L., Douthwaite H., Bradley D., Waldron-Lynch M., Kiermaier A., Eng-Wong J., Dang C., and for the BERENICE Study Group Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. [2018] *Annals of Oncology* (29) 3 : 646-653
171. Talhaoui I., Bernal M., Mullen J.R., Dorison H., Palancade B., Brill S.J., and Mazon G. Slx5-Slx8 ubiquitin ligase targets active pools of the Yen1 nuclease to limit crossover formation. [2018] *Nature Communications* (9) 1 : 5016
172. Touat M., Sourisseau T., Dorvault N., Chabanon R.M., Garrido M., Morel D., Krastev D.B., Bigot L., Adam J., Frankum J.R., Durand S., Pontoizeau C., Souquere S., Kuo M.S., Sauvaigo S., Mardakheh F., Sarasin A., Olausen K.A., Friboulet L., Bouillaud F., Pierron G., Ashworth A., Lombes A., Lord C.J., Soria J.C., and Postel-Vinay S. DNA repair deficiency sensitizes lung cancer cells to NAD⁺ biosynthesis blockade. [2018] *Journal of Clinical Investigation* (128) 4 : 1671-1687
173. Vale C.L., Fisher D.J., White I.R., Carpenter J.R., Burdett S., Clarke N.W., Fizazi K., Gravis G., James N.D., Mason M.D., Parmar M.K.B., Rydzewska L.H., Sweeney C.J., Spears M.R., Sydes M.R., and Tierney J.F. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. [2018] *Annals of Oncology* (29) 5 : 1249-1257
174. Van Baak T.E., Coarfa C., Dugue P.A., Fiorito G., Laritsky E., Baker M.S., Kessler N.J., Dong J., Duryea J.D., Silver M.J., Saffari A., Prentice A.M., Moore S.E., Ghantous A., Routledge M.N., Gong Y.Y., Herceg Z., Vineis P., Severi G., Hopper J.L., Southey M.C., Giles G.G., Milne R.L., and Waterland R.A. Epigenetic supersimilarity of monozygotic twin pairs. [2018] *Genome Biology* (19) 1 : 2
175. Walpole S., [...], Cabaret O., [...], Brescacc de Pailleters B., and Hayward N.K. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. [2018] *Journal of the National Cancer Institute* (110) 12 : 1328-1341
176. Willekens C., Renneville A., Broutin S., Saada V., Micol J.B., Delahousse J., Poinignon V., Bories C., Berthon C., Itzykson R., Boissel N., Quivron C., Terroir-Cassou-Mounat M., Bosq J., Preudhomme C., Paci A., Penard-Lacronique V., and de Botton S. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. [2018] *Leukemia* (32) 9 : 2008-2012
177. Wu X., Kabalane H., Kahli M., Petryk N., Laperrouzaz B., Jaszczyszyn Y., Drillon G., Nicolini F.E., Perot G., Robert A., Fund C., Chibon F., Xia R., Wiels J., Argoul F., Maguer-Satta V., Arneodo A., Audit B., and Olivier H. Developmental and cancer-associated plasticity of DNA replication preferentially targets GC-poor, lowly expressed and late-replicating regions. [2018] *Nucleic Acids Research* (46) 19 : 10157-10172
178. Yamazaki T., Souquere S., Chujo T., Kobelke S., Chong Y.S., Fox A.H., Bond C.S., Nakagawa S., Pierron G., and Hirose T. Functional Domains of NEAT1 Architectural lncRNA Induce Paraspeckle Assembly through Phase Separation. [2018] *Molecular Cell* (70) 6 : 1038-1053
179. Yates L.R., Seoane J., Le Tourneau C., Siu L.L., Marais R., Michiels S., Soria J.C., Campbell P., Normanno N., Scarpa A., Reis-Filho J.S., Rodon J., Swanton C., and Andre F. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. [2018] *Annals of Oncology* (29) 1 : 30-35
180. Zajac O., Raingeaud J., Libanje F., Lefebvre C., Sabino D., Martins I., Roy P., Benatar C., Canet-Jourdan C., Azorin P., Polrot M., Gonin P., Benbarche S., Souquere S., Pierron G., Nowak D., Bigot L., Ducreux M., Malka D., Lobry C., Scoazec J.Y., Eveno C., Pocard M., Perfettini J.L., Elias D., Dartigues P., Goere D., and Jaulin F. Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. [2018] *Nature Cell Biology* (20) 3 : 296-306
181. Zarkovic G., Belousova E.A., Talhaoui I., Saint-Pierre C., Kutuzov M.M., Matkari-mov B.T., Biard D., Gasparutto D., Lavrik O.I., and Ishchenko A.A. Characterization of DNA ADP-ribosyltransferase activities of PARP2 and PARP3: new insights into DNA ADP-ribosylation. [2018] *Nucleic Acids Research* (46) 5 : 2417-2431



www.gustaveroussy.fr

114, rue Édouard-Vaillant
94805 Villejuif Cedex - France

